$NSSC to Present at 13th Annual #ImperialCapitalSecurityConference Dec 3 #IoT

AMITYVILLE, N.Y., Nov. 30, 2016  — NAPCO Security Technologies (NASDAQ: NSSC) one of the world’s leading solutions providers and manufacturers of high tech electronic intrusion security, IoT connected home, video and fire systems, as well as enterprise-class access control and door locking products today announced that Richard Soloway, CEO, will present at the 13^th Annual Imperial Capital Security Conference in New York, NY.

NAPCO management is scheduled to present on December 8 at 9:30 AM ET with one-on-one meetings held throughout the conference. NAPCO management will be discussing two key paradigm shifts in its business: the addition of recurring monthly revenue and new products that address the urgent need for increased school security.

The presentation will be webcast live and available for replay in the Investor Relations section of NAPCO’s website at www.napcosecurity.com.

To receive additional information, request an invitation or to schedule a one-on-one meeting, please contact Imperial Capital or Patrick McKillop, Director IR for NAPCO at pmckillop@napcosecurity.com.

About NAPCO Security Technologies, Inc.

NAPCO Security Technologies, Inc. is one of the world’s leading solutions providers and manufacturers of high-technology electronic security (including recurring service fee revenue), IoT connected home, video, fire alarm, access control and door locking systems. The Company consists of four Divisions: NAPCO, its security and IoT connected home segment, plus three wholly-owned subsidiaries: Alarm Lock, Continental Instruments, and Marks USA. Headquartered in Amityville, New York, its products are installed by tens of thousands of security professionals worldwide in commercial, industrial, institutional, residential and government applications. NAPCO products have earned a reputation for innovation, technical excellence and reliability, positioning the Company for growth in the multi-billion dollar and rapidly expanding electronic security market. For additional information on NAPCO, please visit the Company’s web site at http://www.napcosecurity.com.

Safe Harbor Statement

This press release contains forward-looking statements that involve numerous risks and uncertainties. Actual results, performance or achievements could differ materially from those anticipated in such forward-looking statements as a result of certain factors, including those set forth in the Company’s filings with the Securities and Exchange Commission.

Contact:
Patrick McKillop
Director of Investor Relations
NAPCO Security Technologies, Inc.
OP: 800-645-9445 x 374
CP: 516-404-3597
pmckillop@napcosecurity.com

$SPCB Lands $4.5 million #GPS #Tracking #Monitoring Project in #Asia

The project has potential to expand by additional modules in value ranging from $1 to $4 million in the next 3 months

HERZLIYA, Israel, November 30, 2016  —

SuperCom (Nasdaq: SPCB), a global provider of secure solutions for the e-Government, Public Safety, HealthCare, and Finance sectors, today announced that it has been selected by a new Asian national government customer to deploy a turnkey Electronic GPS Tracking and Monitoring Turn-Key system. The deployment is expected to be completed by end of Q2 2017.

SuperCom expects this program to begin by GPS tracking and monitoring of several thousands of units simultaneously, with potential for further growth. The project was won through a formal competitive bid process with other established industry players. SuperCom expects to complete the deployment and revenue recognition of over 80% of the contract value within 6 months of contract signing.

About SuperCom

Since 1988, SuperCom has been a global provider of traditional and digital identity solutions, providing advanced safety, identification and security solutions to governments and organizations, both private and public, throughout the world. Through its proprietary e-Government platforms and innovative solutions for traditional and biometrics enrollment, personalization, issuance and border control services, SuperCom has inspired governments and national agencies to design and issue secured Multi-ID documents and robust digital identity solutions to its citizens and visitors. SuperCom offers advanced, secure mobile payments ranging from mobile wallet to mobile POS, using a set of components and platforms to enable secure mobile payments and financial services. SuperCom is a global provider of a unique all-in-one field-proven RFID & mobile PureSecurity advanced solutions suite, accompanied by advanced complementary services for various industries, including healthcare and homecare, security and safety, community public safety, law enforcement, electronic monitoring, livestock monitoring, and building and access automation.

SuperCom’s website: http://www.supercom.com

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Statements preceded or followed by or that otherwise include the words “believes”, “expects”, “anticipates”, “intends”, “projects”, “estimates”, “plans”, and similar expressions or future or conditional verbs such as “will”, “should”, “would”, “may” and “could” are generally forward-looking in nature and not historical facts. Forward-looking statements in this release also include statements about business and economic trends. Investors should also consider the areas of risk described under the heading “Forward Looking Statements” and those factors captioned as “Risk Factors” in the Company’s periodic reports under the Securities Exchange Act of 1934, as amended, or in connection with any forward-looking statements that may be made by the Company. These statements are subject to known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements arising from the annual audit by management and the Company’s independent auditors. The Company undertakes no obligation to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise, after the date of this press release.
Investor Relations Contacts:
Brett Maas / Rob Fink
Hayden IR
+1-(646)-536-7331 / +1-(646)-415-8972

Company Contact:
Ordan Trabelsi, President, Americas
Tel: +1-212-675-4606

$RVEN #REIT #Acquires 97 #SFR Portfolio in #Houston, #Texas

LA JOLLA, Calif., Nov. 30, 2016  — Reven Housing REIT, Inc. (“Reven” or the “Company”) (NASDAQ:RVEN) today announced that it has acquired a portfolio of 97 single-family homes in Houston, Texas.  The purchase price for the portfolio was approximately $9,091,000, exclusive of closing costs.  The Company funded the purchase by utilizing proceeds from its most recent public offering.  As part of the initial closing of the public offering the Company up-listed to NASDAQ in September 2016. The acquired properties average 1,482 square feet and are mostly three-bedroom, two bath homes.  Of the acquired properties, 55 are currently subject to one-year leases, 5 are vacant, and 37 are subject to month-to-month leases.

Chad M. Carpenter, Chairman and Chief Executive Officer of Reven, commented, “We are very pleased with our new portfolio acquisition of homes in Houston. This market has proved to be one of our strongest markets. Reven now owns 624 homes in the southeast U.S., primarily in Houston, Jacksonville, Memphis and Atlanta.”

Michael Soni, Senior Investment Advisor who is in charge of acquisitions for Reven states, “This portfolio of homes is similar to, and complements, our existing portfolio. This acquisition increases our total portfolio of homes in Houston to 265.”

Additional information regarding the acquisition of the Houston portfolio can be found in the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on November 30, 2016.

About Reven Housing REIT, Inc.
Reven Housing REIT, Inc., (NASDAQ:RVEN) engages in the acquisition and ownership of portfolios of occupied single family rental properties in the United States. RVEN currently owns and operates SFR’s in Florida, Georgia, Mississippi, Tennessee and Texas.

$MTBC #SeeThruEquity Issues Update

NEW YORK, NY / November 30, 2016 / SeeThruEquity, a leading independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced it has issued an update on Medical Transcription Billing, Corp. (NASDAQ CM: MTBC).

The report is available here: MTBC November Update Note.

Based in Somerset, NJ Medical Transcription Billing, Corp. (NASDAQ CM: MTBC) is a healthcare information technology company that provides a fully integrated suite of web-based solutions and related business services to hospital-based and private healthcare providers. MTBC became a public company in July 2014, after several years of strong growth through both acquisitions and organic means as a private healthcare technology company. Through its flagship software-as-a-service (SAAS) platform Practice Pro, MTBC “brings big practice solutions” to over 750 small and medium sized medical practices, helping more than 1,700 providers grow and track sales, streamline operations, and use data to facilitate better business and clinical decision making. MTBC recently reported 3Q16 results, with highlights as follows:

• Revenues came in at $5.3mn and were $15.7mn for the first nine months of the year.
• Management-defined adjusted EBITDA was positive $0.13mn and $0.20mn for the quarter and first nine months of the year, respectively.
• GAAP EPS was a loss of $0.17 per share.

MTBC announces 3Q16 results, expands on MediGain deal

On November 11, 2016, MTBC held a conference call with investors and stakeholders to discuss 3Q16 results and the recent acquisition of MediGain LLC, a Texas-based medical billing specialist, which MTBC management expects to be its largest acquisition. Management clarified its expectations for MediGain on the call. MediGain is expected to add nearly 200 new customers, and is expected to be accretive to adjusted EBITDA in 2017E. MTBC also indicated that MediGain will add to its sales resources, since there were no US sales and marketing employees prior to the acquisition. MediGain also adds low cost operations based in Asia. Management also predicted $10mn in revenues from MediGain in 2017, at the high end of its prior estimate of $8mn- $10mn.

Revenue rises, MTBC generates adjusted EBITDA

During 3Q16, MTBC revenues rose sequentially to $5.3mn in 3Q16 from $5.1mn in 2Q16. Revenues did fall on a YoY basis, as the company continues to emerge from the impact of customer churn at the end of 2015. For the first nine months of 2016, MTBC recorded revenues of $15.7mn, versus $17.7mn in the comparable year-ago period. Notably, MTBC generated management-defined, adjusted EBITDA for the fourth consecutive quarter, with adjusted EBITDA coming in at $0.13mn in the quarter and $0.2mn for the first nine months of the year.

Updating estimates; maintaining price target

We are updating our 2016 estimates following recent results. Although 4Q16 is seasonally strong for MTBC, and management guided for record revenues during the quarter, the company’s last public guidance for 2016 had assumed the closing of a large acquisition earlier in the year. Consequently, we now expect 2016 revenues of $23.7mn and GAAP EPS of ($0.83). We are maintaining 2017E revenue estimate of $35mn. Our price target remains $3.85.

About MTBC

MTBC is a healthcare information technology company that provides a fully integrated suite of proprietary web-based solutions, together with related business services, to healthcare providers practicing in ambulatory care settings. Our integrated Software-as-a-Service (or SaaS) platform helps our customers increase revenues, streamline workflows and make better business and clinical decisions, while reducing administrative burdens and operating costs. MTBC’s common stock trades on the NASDAQ Capital Market under the ticker symbol “MTBC,” and its Series A Preferred Stock trades on the NASDAQ Capital Market under the ticker symbol “MTBCP.”

www.mtbc.com

About SeeThruEquity

Since its founding in 2011, SeeThruEquity has been committed to its core mission: providing impactful, high quality research on underfollowed smallcap and microcap equities. SeeThruEquity has pioneered an innovative business model for equity research that is not paid for and is unbiased. SeeThruEquity is the host of acclaimed investor conferences that are the ultimate event for publicly traded companies with market capitalizations less than $1 billion.

SeeThruEquity is approved to contribute its research reports and estimates to Thomson One Analytics (First Call), the leading estimates platform on Wall Street, as well as Capital IQ and FactSet. SeeThruEquity maintains one of the industry’s most extensive databases of opt-in institutional and high net worth investors. The firm is headquartered in Midtown Manhattan in New York City.

For more information visit www.seethruequity.com.

$EXPI #MarseeWilhems Team Joins @eXpRealty in #Tucson

The Agent-Owned Cloud Brokerage(R) Welcomes #1 Team in Arizona and #16 Overall in the United States

$QLTI Complete #Merger #NameChange to #NovelionTherapeutics Inc.

— Transaction creates strong, diversified rare-disease focused portfolio
— Novelion Therapeutics completes concurrent financing of approximately $22 million
— Company to host conference call today at 4:30 p.m. ET

CAMBRIDGE, Mass. and VANCOUVER, B.C., Nov. 29, 2016  — Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) (“Aegerion”) and QLT Inc. (NASDAQ:QLTI) (TSX:QLT) (“QLT”) today announced the completion of their merger transaction, as a result of which Aegerion is now an indirect wholly-owned subsidiary of QLT. In conjunction with the closing of the merger, QLT changed its name to Novelion Therapeutics Inc. (“Novelion”). Novelion’s common shares will begin trading on The NASDAQ Global Select Market under the symbol NVLN as of market open on November 30, 2016 and on the Toronto Stock Exchange under the symbol NVLN as of market open on or about December 1, 2016.  In the interim, Novelion’s shares will continue to trade on the NASDAQ Global Select Market under the symbol QLTI and Toronto Stock Exchange under the symbol QLT.

“We are pleased to announce the closing of this transaction,” said Mary Szela, Chief Executive Officer of Novelion. “We expect that our multi-asset portfolio of approved treatments, coupled with our pipeline, global commercial capabilities, strong intellectual property for our therapies, and improved financial position, will allow Novelion to create significant value for shareholders, while also enabling us to invest for growth. We look forward to executing on our mission of meaningfully impacting the lives of patients suffering from rare diseases.”

In conjunction with the closing of the merger, a broad-based investor syndicate, including Deerfield, Armistice Capital, Broadfin Capital, Healthcare Value Capital, JW Asset Management, K2 & Associates Investment Management, Sarissa Capital, Jason Aryeh, and Tiger Legatus Capital Management, invested approximately $22 million in QLT. Novelion has an unrestricted cash balance of over $100 million to support future operations and potential targeted business development initiatives.

The holders of shares of Aegerion common stock outstanding immediately prior to the merger will receive, as merger consideration, 1.0256 Novelion common shares in exchange for each share of Aegerion common stock held.

Novelion will operate mainly under the leadership of Aegerion’s management team prior to the merger, including Mary Szela as Chief Executive Officer, Gregory Perry as Chief Financial and Administrative Officer, and John Orloff as Executive Vice President, Head of Research and Development. The newly constituted Board of Directors is comprised of ten members – four Aegerion designees, four QLT designees, one designee from Broadfin Capital and one designee from Sarissa Capital Management. Novelion’s principal headquarters are located in Vancouver, British Columbia, with business operations in Cambridge, Massachusetts.

Financial Guidance

• Expect full year 2016 global net product sales for JUXTAPID® and MYALEPT® to be between $145 and $150 million.
• Expect to provide Novelion’s full year 2017 financial guidance in early January.

Upcoming Milestones

• Expect to submit a marketing authorization application for metreleptin as a potential treatment for GL and a subset of partial lipodystrophy patients in the EU in the fourth quarter of 2016.
• Following regulatory and pricing approval for JUXTAPID in Japan for the treatment of homozygous familial hypercholesterolemia (HoFH), we expect to launch in January 2017.

Conference Call & Webcast:
Novelion will host a conference call and webcast at 4:30 p.m. ET today. The live call may be accessed by phone by calling (866) 516-3002 (U.S.) or (760) 298-5082 (international). The webcast may be accessed on the Investor Relations section of Novelion’s website, www.novelion.com, to be launched following the close of market today.

About Novelion Therapeutics Inc.
Novelion Therapeutics is a biopharmaceutical company dedicated to developing new standards of care for individuals living with rare diseases. The company seeks to advance its portfolio of rare disease therapies by investing in science and clinical development. Novelion has a diversified commercial portfolio through its indirect subsidiary, Aegerion Pharmaceuticals, Inc., which includes MYALEPT® and JUXTAPID®, and is also developing zuretinol acetate for the treatment of inherited retinal disease caused by underlying mutations in RPE65 or LRAT genes.

Forward-Looking Statements

This press release contains forward-looking statements, including statements regarding: financial projections for 2016; the anticipated approval of MYALEPT in the EU and other regulatory activities related to MYALEPT; the planned launch of JUXTAPID in JAPAN; and the anticipated growth of the Novelion business and the creation of significant value for our stockholders. These forward-looking statements are neither promises nor guarantees of future performance, and are subject to a variety of risks and uncertainties, many of which are beyond our control, which could cause actual results to differ materially from those contemplated in these forward-looking statements. In particular, the risks and uncertainties include: the possibility that the anticipated benefits and synergies from the proposed merger cannot be fully realized or may take longer to realize than expected; the possibility that costs or difficulties related to the integration of Aegerion and QLT operations will be greater than expected; the risk that market acceptance of JUXTAPID and MYALEPT in the U.S. may not continue at the levels we expect, and may be lower outside the U.S., including in Brazil, than we expect; the risk that the conversion of prescriptions for JUXTAPID or MYALEPT into patients on therapy may be lower than we expect or the drop-out rate may be higher than we expect; the risk that the prevalence of the diseases Aegerion’s products treat, or that we are pursuing treatment for, may be lower than we estimate, and that it may be more difficult to identify patients than we expect; the risk that the side effect profile or other results for Aegerion’s products in commercial use and in further clinical studies are inconsistent, in scope and severity, with the side effect profile and other results observed in the pivotal study of each drug; the risk that the negative impact of the launch of PCSK9 inhibitors on JUXTAPID sales will be greater than we currently expect, particularly in the U.S., where the negative impact has been greater than we expected to date, or that other competitive products will negatively impact our results; the risk that private or government payers may refuse to reimburse Aegerion’s or our products, or may impose onerous restrictions that hinder reimbursement or significantly limit or cap the price Aegerion or we charge or the number of reimbursed patients who receive products; the risk that revisions to the JUXTAPID Risk Evaluation and Mitigation Strategies (REMS) Program may negatively impact U.S. sales; the risk that our business may be negatively impacted if there are more Medicaid patients prescribed MYALEPT than we expect; the risk that named patient sales in Brazil and other key countries outside the U.S. may not be at the levels we expect; the risk that regulatory authorities in regions or countries where either of Aegerion’s products is not yet approved may refuse to approve such products or additional indications for such products, such approvals are not made on a timely basis or such approvals impose significant restrictions or require additional development; the risk that exchange rates will negatively impact the amount of net product sales recognized; the risk that the initiation of future clinical trials may be delayed; the risk that we will not be successful in our lifecycle management or business development efforts; the risk that Aegerion’s and our patent portfolios and marketing and data exclusivity may not be as strong as we anticipate; the risk of unexpected manufacturing issues affecting future supply; the risk that Aegerion incurs more costs than we expect in responding to investigations, defending litigation and resolving litigation; the risk that any of the foregoing may cause product sales revenue to be lower than we expect, or that we may incur unanticipated expenses in connection with our activities; the risk that Aegerion may not be able to enter into agreements with third parties respect to lomitapide as part of our strategic reevaluation on acceptable terms, or at all, and the risk that our reputation may be harmed and we may be affected by negative publicity if Aegerion is unable to enter into agreements with third parties with respect to supplying lomitapide in the markets from which Aegerion intends to withdraw; the risk that we may not be able to successfully execute strategic plans, including our cost-reduction program; and the other risks inherent in the commercialization, drug development and regulatory approval process. In addition, Aegerion’s agreement in principle with the U.S. Department of justice (“DOJ”) and the U.S. Securities and Exchange Commission (“SEC”) relating to the investigations by these agencies and the terms of potential final settlements with these agencies include risks associated with the required approvals of final settlement terms by relevant government agencies, such as the proposed settlement with the DOJ being subject to approval of supervisory personnel within the DOJ and relevant federal and state agencies and approval by a U.S. District Court judge of the criminal plea and sentence and the civil settlement agreement, and the proposed settlement with the SEC being subject to review by other groups in the SEC and approval by the Commissioners of the SEC.  The terms of the preliminary agreements in principle may change following further negotiations.  The amount and terms of any final settlement may be substantially higher and less favorable than we anticipate based on the terms of the preliminary agreements in principle.  Final settlement terms could include the imposition of additional penalties, further limiting Aegerion’s ability to conduct its business as currently conducted and as planned to be conducted. Additionally, the DOJ and the SEC each likely will outline their views of the factual background in connection with any final settlement.  The government’s recitation of their assessment of the background could lead to additional legal claims or investigations by state government entities or private parties and may have adverse effects on Aegerion’s existing class action litigation, commercial operations and contracts.  For additional disclosure regarding these and other risks we face, see the disclosure contained in the “Risk Factors” section of Aegerion’s Quarterly Report on Form 10-Q filed on November 4, 2016, QLT’s Annual Report on Form 10-K filed on February 25, 2016 (and amended on April 29, 2016) and Quarterly Report on Form 10-Q filed on November 1, 2016 and each company’s other public filings with the SEC, available on the SEC’s website at http://www.sec.gov. We undertake no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise, except as required by law.

Investors and others should note that we communicate with our investors and the public using our company websites, www.aegerion.com and www.qltinc.com, including, but not limited to, company disclosures, investor presentations and FAQs, SEC filings, press releases, public conference calls transcripts and webcast transcripts. The information that we post on these websites could be deemed to be material information. As a result, we encourage investors, the media and others interested to review the information that we post there on a regular basis. The contents of our website shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended.

CONTACT:                          
Amanda Murphy, Associate Director, Investor & Public Relations                                 
857-242-5024  
Amanda.Murphy@aegerion.com

$CSBR 50 Percent #Revenue #Growth

HACKENSACK, N.J., Nov. 29, 2016  — Champions Oncology, Inc. (Nasdaq: CSBR), engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced its financial results for the second quarter ended October  31, 2016.

Second Quarter and Recent Business Highlights:

• Record quarterly revenue of $4.5 million;
• Second quarter revenue growth of 50%; 59% growth in TOS segment;
• Reaffirms annual revenue guidance for current fiscal year of $16 – 18 million;
• Quarterly cash burn reduced to less than $150,000 with $4.3 million of cash at the end of the quarter;
• Signed $2 million pre-clinical pharmacology contract with large pharmaceutical customer; and
• Initiates leadership transition process for calendar year 2017 to drive innovation and accelerated growth.

Joel Ackerman, CEO of Champions, commented, “This was truly a milestone quarter for Champions.  We have been focused over the last 2 years on achieving profitability while continuing to invest in expanding our technology and products.  We reached this important step in the Company’s evolution by growing our customer base, delivering high quality studies and managing our costs.  With 50% revenue growth and a lower cost base than last year, we have delivered on this ambitious objective ahead of schedule.  Looking forward, we remain confident we will achieve our projected revenue of $16 – 18 million for our fiscal year ending April 2017.  This quarter’s profitability was achieved without any one-time revenue items or non-recurring events while continuing to invest approximately $4 million per year in innovative research and development.  We are now poised to shift our attention to the next phase of strategic growth.”

New Strategic Emphasis

Dr. Ronnie Morris, the company’s President added, “We have spent considerable time with the Board of Directors developing the next phase of our strategic plan.  We have concluded that now is the right time to shift the emphasis of the company’s strategic efforts towards innovation.  We are committed to increasing our profitability and improving cash flow while simultaneously pursuing an accelerated growth path driven by new uses of PDX and related product offerings.  We have built a customer base of almost 150 pharmaceutical and biotech companies that work with Champions because of our powerful platform and operational excellence.  Many customers have talked to us about expanding our technology and platform to provide them with enhanced products and services based on our current offering.  We are now ramping up our efforts to develop these innovations and meet our customers’ demands.”

Senior Leadership Changes

To align the Company’s senior management resources with this increased focus on innovation, the Company is announcing a re-alignment of certain roles at Champions.  Dr. Philip Breitfeld, a recent addition to the company’s board of directors, will assume the position of Chief Strategic and Innovation Officer of the Company.  Dr. Breitfeld, a medical oncologist, has over 30 years of experience in oncology research and drug development.  He has held positions as Senior Medical Director and Head of the Global Clinical Oncology Development Unit in the U.S. for Merck KGaA and as Associate Chief Medical Officer at Biocryst.   Most recently he was Global Vice President at Quintiles’ responsible for the Therapeutic Centers of Excellence, where his focus was business development and innovation. This change is anticipated to occur during December 2016.

In addition, Joel Ackerman, current CEO, will shift his role to Chairman of the Board of Directors.  Dr. Ronnie Morris, current President of Champions, will assume the role of CEO.  Dr. David Sidransky, the founder of Champions and current Chairman of the Board of Directors, will assume the role of lead director.   These changes will take effect in January 2017.  Dr. David Sidransky commented, “Now that we have proven the business model, we wanted to align the senior team with the new strategic emphasis of the company.  As President of Champions for the last six years, Ronnie is intimately familiar with every aspect of the company’s business. We have developed a plan that ensures a smooth and gradual transition to the new strategic phase.  We look forward to Joel’s continued involvement in the oversight of the company’s financial and operational performance.  I look forward to working closely with Ronnie, Phil and the rest of the team on the next phase of growth.”

Financial Results

For the second quarter of fiscal 2017, revenue was $4.5 million, as compared to $2.9 million for the second quarter 2016, an increase of 50%. Total operating expense for the second quarter fiscal 2017 was $5 million as compared to $5.5 million for the second quarter 2016, a decrease of 9.4%. Revenue was $8.1 million and $5.8 million for the six months ended October 31, 2016 and 2015, respectively, an increase of $2.3 million or 40.3%.

For the second quarter of fiscal 2017 and 2016, Champions reported a loss from operations of $493,000 and $2.5 million, respectively. Excluding stock-based compensation of $535,000 and $748,000 for the three months ended October  31, 2016 and 2015, respectively, Champions recognized  a gain from operations of $42,000 and loss from operations of $1.75 million for second quarter 2017 and 2016, respectively.

For the six months ended October 31, 2016 and 2015, Champions reported a loss from operations of $3.0 million and $5.4 million, respectively, a decrease of $2.4 million or (44%). Excluding stock-based compensation of $1.7 million and $1.5 million for the six months ended October 31, 2016 and 2015, Champions recognized loss from operations of $1.3 million and $3.9 million, respectively.

Net cash used in operations was $2.6 and $5.1 million for the six months ended October 31, 2016 and 2015, respectively, a decrease of $2.5M or (49.4%). The reduction in cash burn is the result of revenue growth, aggressive expense management and payments received in advance of revenue recognition.

Net cash used in operations for the second quarter of fiscal 2017 was $117,000.  The company ended the quarter with $4.3 million of cash and cash equivalents on the balance sheet.

Translational Oncology Services (TOS) revenue was $4.0 million and $2.5 million for the three months ended October 31, 2016 and 2015, respectively, an increase of $1.5 million or 59.4%. The increase is due to increased bookings in prior quarters, both in the number and size of the studies, and the addition of new customers.

TOS cost of sales was $1.8 million and $1.4 million for the three months ended October 31, 2016 and 2015, respectively, an increase of $400,000, or 26.7%. For the three months ended October 31, 2016 and 2015, gross margin for TOS was 53.8% and 41.9%, respectively. The increase in TOS cost of sales was due to an increase in TOS studies. The improvement in gross margin was due to higher TOS revenue leveraged off the fixed cost component of the lab and effective management of the variable lab costs.

Personalized Oncology Services (POS) revenue was $497,000 and $486,000 for the three months ended October 31, 2016 and 2015, respectively, an increase of $11,000 or 2.3%.

POS cost of sales was $374,000 and $568,000 for the three months ended October 31, 2016 and 2015, respectively, a decrease of $194,000, or (34.2%). For the three months ended October 31, 2016 and 2015, gross margin for POS was 24.7% and negative (16.9%), respectively. The improvement is attributed to the increase in higher margin sequencing revenue and aggressively managing our lab costs.

Research and development expense was $1 million and $919,000 for the three months ended October 31, 2016 and 2015, respectively, an increase of $89,000, or 9.7%. Sales and marketing expense for the three months ended October 31, 2016 and 2015 was $717,000 and $834,000 respectively, a decrease of $117,000, or (14.0%). The decrease is due to the consolidation of sales and marketing personnel resources of the POS and TOS division. General and administrative expense was $1.0 million and $1.7 million for the three months ended October 31, 2016 and 2015, respectively, a decrease of $700,000 or 39.9%. The decrease is primarily due to a decrease of $213,000 in stock compensation expense, along with reductions in legal and audit fees $150,000 and personnel related expenses of $100,000.

Conference Call Information:

The Company will host a conference call today at 4:30 p.m. EST (1:30 p.m. PST) to discuss its second quarter financial results. To access the conference call, domestic participants should dial 800-875-3456, Canadian participants should dial 800-648-0973, and international participants should dial 302-607-2001. The participant passcode is “Champions”.

Full details of the Company’s financial results will be available Wednesday December 14, 2016 in the Company’s Form 10-Q at www.championsoncology.com.

* Non-GAAP Financial Information

See the attached Reconciliation of GAAP net loss to non-GAAP net loss for an explanation of the amounts excluded to arrive at non-GAAP net loss and related non-GAAP net loss per share amounts for the three months ended October 31, 2016 and 2015. Non-GAAP financial measures provide investors and management with supplemental measures of operating performance and trends that facilitate comparisons between periods before and after certain items that would not otherwise be apparent on a GAAP basis.  Certain unusual or non-recurring items that management does not believe affect the Company’s basic operations do not meet the GAAP definition of unusual or non-recurring items.  Non-GAAP net loss and non-GAAP loss per share are not, and should not be viewed as a substitute for similar GAAP items.  Champions’ defines non-GAAP dilutive loss per share amounts as non-GAAP net loss divided by the weighted average number of diluted shares outstanding.  Champions’ definition of non-GAAP net loss and non-GAAP diluted loss per share may differ from similarly named measures used by others.

About Champions Oncology, Inc.

Champions Oncology, Inc. is engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs.  The Company’s TumorGraft technology platform is a novel approach to personalizing cancer care based upon the implantation of primary human tumors in immune deficient mice followed by propagation of the resulting engraftments, or TumorGrafts, in a manner that preserves the biological characteristics of the original human tumor in order to determine the efficacy of a treatment regimen.  The Company uses this technology in conjunction with related services to offer solutions for two customer groups:  Personalized Oncology Solutions, in which results help guide the development of personalized treatment plans, and Translational Oncology Solutions, in which pharmaceutical and biotechnology companies seeking personalized approaches to drug development can lower the cost and increase the speed of developing new drugs. TumorGrafts are procured through agreements with a number of institutions in the U.S. and overseas as well as through Champions’ Personalized Oncology Solutions business. For more information, please visit www.championsoncology.com.

This press release may contain “forward-looking statements” (within the meaning of the Private Securities Litigation Act of 1995) that inherently involve risk and uncertainties.  Champions Oncology generally uses words such as “believe,” “may,” “could,” “will,” “intend,” “expect,” “anticipate,” “plan,” and similar expressions to identify forward-looking statements.  One should not place undue reliance on these forward-looking statements.  The Company’s actual results could differ materially from those anticipated in the forward-looking statements for many unforeseen factors.  See Champions Oncology’s Form 10-K for the fiscal year ended April 30, 2016 for a discussion of such risks, uncertainties and other factors.  Although the Company believes the expectations reflected in the forward-looking statements are reasonable, they relate only to events as of the date on which the statements are made, and Champions Oncology’s future results, levels of activity, performance or achievements may not meet these expectations.  The Company does not intend to update any of the forward-looking statements after the date of this press release to conform these statements to actual results or to changes in Champions Oncology’s expectations, except as required by law.

$MSDI Initial #Closing of #PrivatePlacement

$DRAM Finalizes Agreement to #Acquire #USGoldCorp

PRINCETON, N.J., Nov. 29, 2016  — Dataram Corporation (NASDAQ: DRAM), an independent manufacturer of memory products and provider of performance solutions, today announced that it had finalized and filed the third and final amendment to its definitive agreement with U.S. Gold Corp. (“USGC”), a U.S. focused gold exploration and development company.  Under the agreement, Dataram will acquire all of the outstanding shares of U.S. Gold Corp. and USGC subsidiaries.  The original agreement was entered into in June 2016 and has been subsequently amended to reflect the successful capital raise by U.S. Gold, the Series D issuance by Dataram and also, the impact of the reverse split.  The agreement was filed with the Securities and Exchange Commission (SEC) and can be reviewed at www.sec.gov.

The Companies are working to finalize the preliminary S-4/Proxy, which they intend to file with NASDAQ in December 2016.  Once the NASDAQ review is completed, the Dataram will file a definitive S-4/Proxy and will formally present the merger and associated consideration to the shareholders in early 2017 review and approval.

U.S. Gold Corp. controls the Copper King Project, an advanced stage gold exploration project based in Wyoming, which owns certain mining leases and other mineral rights in the Silver Crown Mining District of southeast Wyoming, and has also acquired certain mining claims related to a gold exploration project in Eureka County, Nevada known as the “Keystone Project.”

“While there are always risks, and critical activities can sometimes take longer than planned, Dataram remains fully committed to acquiring U.S. Gold as we remain confident that this is a tremendous opportunity for our shareholders,” stated Mr. Dave Moylan, Dataram’s Chairman and Chief Executive Officer (CEO).  “With any merger or acquisition activity, there are multiple dependencies that each company must address.  U.S. Gold recently completed an extremely successful capital raise intended to directly support exploration activities for both the Copper King and Keystone projects.  The raise helps ensure these exploration efforts are fully funded for several years.  The strong participation in the raise reaffirms our belief that our entry into the natural resources sector, which is intended to diversify risk, will unlock value for our shareholders.  It also reaffirms the acquisition as an economically viable and exciting project given the overall landscape and market opportunity within natural resources.  Additionally, the memory market has been undergoing a sharp increase in DRAM prices since mid-summer, with the Average Selling Price (ASP) of our memory products rising significantly since the July/August timeframe.  In conjunction with the acquisition, we remain focused on making strategic purchases of DRAM components and modules to provide competitive pricing of high quality memory products in the market.”

“We remain enthusiastic about the opportunities created through this acquisition and believe the combined companies will generate significant value for our shareholders,” comments Mr. Edward Karr, CEO and Director of U.S. Gold Corp. “With a strong capital raise completed, we are quickly moving forward on advancing both of our development and exploration projects.”

The transaction is subject to customary closing conditions including regulatory approval and Dataram shareholder approval, and is expected to close by the end of Q1 CY 2017.   ROTH Capital Partners, LLC is acting as the financial advisor to Dataram, and Windels Marx Lane and Mittendorf LLP and Sichenzia Ross Ference Kesner LLP are serving as legal advisors to Dataram.  Laxague Law, Inc. is serving as legal advisor to U.S. Gold.

Dataram’s common stock trades on The NASDAQ Capital Market under the symbol “DRAM.”

About Dataram Corporation
Dataram is an independent manufacturer of memory products and provider of performance solutions that increase the performance and extend the useful life of servers, workstations, desktops and laptops sold by leading manufacturers such as Dell, Cisco, Fujitsu, HP, IBM, Lenovo and Oracle. Dataram’s memory products and solutions are sold worldwide to OEMs, distributors, value-added resellers and end users. Additionally, Dataram manufactures and markets a line of Intel Approved memory products for sale to manufacturers and assemblers of embedded and original equipment. 70 Fortune 100 companies are powered by Dataram. Founded in 1967, the Company is a US based manufacturer, with presence in the United States, Europe and Asia. For more information about Dataram, visit www.dataram.com.

Safe Harbor
Matters discussed in this press release contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. When used in this press release, the words “anticipate,” “believe,” “estimate,” “may,” “intend,” “expect” and similar expressions identify such forward-looking statements. Actual results, performance or achievements could differ materially from those contemplated, expressed or implied by the forward-looking statements contained herein. These forward-looking statements are based largely on the expectations of the Company and are subject to a number of risks and uncertainties. These risks include, but are not limited to, risks and uncertainties associated with the price of the Company’s common stock and its ability to satisfy the continued listing standards of The NASDAQ Stock Market, the impact of economic, competitive and other factors affecting the Company and its operations, markets, products, changes in the price of memory chips, changes in the demand for memory systems, increased competition in the memory systems industry, order cancellations, delays in developing and commercializing new products, risks related  to the Company’s previously announced acquisition target, U.S. Gold Corp., faced by junior exploration companies generally engaged in pre-production activities; maintenance of important business relationships; and other factors described in the Company’s most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K, including  the Risk Factors with respect to U.S. Gold contained in the Current Report on Form 8-K filed on June 13, 2016, filed with the Securities and Exchange Commission, which can be reviewed at www.sec.gov.  The Company has based these forward-looking statements on its current expectations and assumptions about future events.  While management considers these expectations and assumptions to be reasonable, they are inherently subject to significant business, economic, competitive, regulatory, and other risks, contingencies, and uncertainties, most of which are difficult to predict and many of which are beyond the Company’s control.  The Company does not assume any obligations to update any of these forward-looking statements.

For additional information, please contact:

Dataram Corporation
Jeffrey Goldenbaum
Director, Marketing
609-799-0071
info@dataram.com

$SCON Lands $4.5 Million #DOE #NGEM #Award, #Partners w/ TECO-Westinghouse Motors

Collaborating with TECO-Westinghouse Motor Company, Massachusetts Institute of Technology and University of North Texas

AUSTIN, Texas, Nov. 29, 2016  — Superconductor Technologies Inc. (STI) (Nasdaq:SCON) has been selected as prime recipient of the $4.5 million program award provided by the U.S. Department of Energy’s (DOE) Office of Energy Efficiency and Renewable Energy (EERE), on behalf of the Advanced Manufacturing Office, for its Next Generation Electric Machines (NGEM) program. Collaborating with STI is TECO-Westinghouse Motor Company (TWMC), an industry leading manufacturer of electric generators and motors, and renowned academic institutions Massachusetts Institute of Technology (MIT) and University of North Texas (UNT).  The combined team will focus on improving the manufacturing process of superconductive wires to improve performance and yield while reducing cost at high enough temperatures where nitrogen can be used as the cryogenic fluid.

“Advancing these enabling technologies has the potential to boost the competitiveness of American manufacturers and take the development of more efficient electric machines a giant step further,” said Mark Johnson, director of the EERE Advanced Manufacturing Office. “These technology R&D projects aim to significantly improve industrial motors for manufacturing, helping companies who use these motors in manufacturing save energy and money over the long run.”

“We believe that being selected first by our esteemed proposal partners and then winning the DOE award recognizes STI’s unique HTS manufacturing process and our ability to achieve high performance, cost efficiencies and commercial scale capacity,” stated STI’s president and chief executive officer Jeff Quiram. “In addition, the significant wire improvement goals for this program will address our customers’ desire for increased infield magnetic performance and high performance/low cost wire for many applications, such as motors, generators, magnets, power cables and MRI machines. STI expects to transition from R&D to full scale production of motor- and generator-optimized wire during the three-year project plan, which will enable our superconducting technology to be introduced into Next Generation Electrical Machines utilizing high performance/low cost HTS wire.”

TWMC’s president Pat Rogers stated, “TWMC recognized the immense value of superconductor technology for high-power electric machines early, and we are committed to their commercialization. We look forward to collaborating to develop the transformational technology needed to achieve commercial viability of high power superconducting next-generation electric machines.”

MIT’s Plasma Science and Fusion Center Assistant Director Joseph V. Minervini stated, “STI’s goal of high performance at low cost can be a game changer for a wide range of applications, not only at temperatures near liquid nitrogen, but also at lower temperatures.”

UNT’s Assistant Professor Materials and Science Engineering Dr. Marcus L. Young stated, “By bringing together university knowledge and capabilities from MIT and UNT with STI, a world class manufacturer of superconducting materials, and TWMC, the end user and device maker with over 100 years of experience in motor design and application, the full range of research and development to product manufacturing and wide scale commercialization of superconducting materials will be achieved.”

About Superconductor Technologies Inc. (STI)
Superconductor Technologies Inc. is a global leader in superconducting innovation. Its Conductus^® superconducting wire platform offers high performance, cost-effective and scalable superconducting wire. With 100 times the current carrying capacity of conventional copper and aluminum, superconducting wire offers zero resistance with extreme high current density. This provides a significant benefit for electric power transmission and also enables much smaller or more powerful magnets for motors, generators, energy storage and medical equipment. Since 1987, STI has led innovation in HTS materials, developing more than 100 patents as well as proprietary trade secrets and manufacturing expertise. For more than 20 years STI utilized its unique HTS manufacturing process for solutions to maximize capacity utilization and coverage for Tier 1 telecommunications operators. Headquartered in Austin, TX, Superconductor Technologies Inc.’s common stock is listed on the NASDAQ Capital Market under the ticker symbol “SCON.” For more information about STI, please visit http://www.suptech.com.

Safe Harbor Statement
Statements in this press release regarding our business that are not historical facts are “forward-looking statements” that involve risks and uncertainties. Forward-looking statements are not guarantees of future performance and are inherently subject to uncertainties and other factors, which could cause actual results to differ materially from the forward-looking statements. These factors and uncertainties include, but are not limited to: our limited cash and a history of losses; our need to materially grow our revenues from commercial operations and/or to raise additional capital (which financing may not be available on acceptable terms or at all) in the very near future, before cash reserves are depleted (which reserves are expected to be sufficient into the first quarter of 2017), to implement our current business plan and maintain our viability; the performance and use of our equipment to produce wire in accordance with our timetable; overcoming technical challenges in attaining milestones to develop and manufacture commercial lengths of our HTS wire; the possibility of delays in customer evaluation and acceptance of our HTS wire; the limited number of potential customers and customer pressures on the selling prices of our products; the limited number of suppliers for some of our components and our HTS wire; there being no significant backlog from quarter to quarter; our market being characterized by rapidly advancing technology; the impact of competitive products, technologies and pricing; manufacturing capacity constraints and difficulties; the impact of any financing activity on the level of our stock price; the dilutive impact of any issuances of securities to raise capital; the steps required to maintain the listing of our common stock with a U.S. national securities exchange and the impact on the liquidity and trading price of our common stock if we fail to maintain such listing; the cost and uncertainty from compliance with environmental regulations; and local, regional, and national and international economic conditions and events and the impact they may have on us and our customers.

Forward-looking statements can be affected by many other factors, including, those described in the “Business” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of STI’s Annual Report on Form 10-K for the year ended December 31, 2015 and in STI’s other public filings. These documents are available online at STI’s website, www.suptech.com, or through the SEC’s website, www.sec.gov. Forward-looking statements are based on information presently available to senior management, and STI has not assumed any duty to update any forward-looking statements.

Investor Relations Contact
Cathy Mattison or Kirsten Chapman
LHA      +1-415-433-3777       invest@suptech.com

$NETE #Partners with #ConformanceTechnologies, Offering #PCIToolKit to Merchants

Merchants May Access PCI ToolKit(R) Activities in Chinese, English, Russian and Spanish

$REPH #Positive #TopLine #Results Phase III #ClinicalTrial #IVMeloxicam

IV Meloxicam Achieves Primary Endpoint of Statistically Significant Reduction in SPID24 in Patients with Acute Postoperative Pain Following Abdominoplasty Surgery

Ten Secondary Endpoints Also Met

Company Estimates Filing US NDA in Summer 2017

MALVERN, Pa., Nov. 28, 2016  — Recro Pharma, Inc. (Nasdaq:REPH), a revenue generating specialty pharmaceutical company focused on products for hospital and ambulatory care settings, currently developing non-opioid products for the treatment of serious acute pain, today announced positive results from its second of two Phase III clinical trials evaluating intravenous (IV) meloxicam for the treatment of acute postoperative pain.  In this trial, IV meloxicam achieved the primary endpoint of a statistically significant difference in Summed Pain Intensity Difference (SPID) over the first 24 hours (SPID24), compared to placebo, in patients following abdominoplasty surgery. With the positive data from this study, the Company believes this completes the efficacy program for the IV meloxicam New Drug Application (NDA).

In this multicenter, randomized, double-blind, placebo-controlled clinical trial, 219 patients were enrolled and randomly assigned to receive a postoperative regimen of IV meloxicam (30mg bolus injection) or placebo in a 1:1 ratio, once every 24 hours. The IV meloxicam treatment arm demonstrated a statistically significant reduction in SPID24 (p=0.0145) compared to the placebo arm.  The study also achieved statistical significance for 10 of the secondary endpoints, including statistically significant differences in SPID12 (p=0.0434), time to perceptible pain relief (p=0.0050), subjects with ≥30% improvement at 24 hours (p=0.0178), number of times patients required rescue in the first 24 hours after randomization (p=0.0275), as well as number of times rescued from 24 to 48 hours (p=0.0009), and several other pain relief metrics, compared to placebo.

The safety results demonstrated that IV meloxicam was well tolerated with no difference in serious adverse events (SAEs) related to bleeding for IV meloxicam treated patients versus placebo (1 each).  There were two additional SAEs observed in the placebo group.  The most common (≥2% in the IV meloxicam group) adverse events (AEs) were nausea, headache, vomiting, and dizziness.  The incidence of these events was lower than those observed in the placebo group.  The majority of AEs were mild in nature and one patient in the placebo group discontinued treatment due to an adverse event of post-procedural bleeding.

There were no meaningful differences between treatment groups in vital signs, ECGs or clinical lab assessments.

“The data from this trial demonstrated that IV meloxicam achieved a statistically significant difference in SPID24 pain relief following abdominoplasty surgery, a favorable safety and tolerability profile, and impressive impact on the number of times patients required rescue throughout the 0-24 and 24-48 hour periods, as well as the percent of subjects with ≥30% improvement at 24 hours,” said Neil Singla, M.D., Chief Scientific Officer of Lotus Clinical Research. “These data are important because they show that, if approved, IV meloxicam has the potential to be a new, non-opioid alternative for patients with moderate-to-severe pain following soft tissue surgery.”

“The positive outcome from this second pivotal trial continues to demonstrate the efficacy of IV meloxicam in the acute postoperative setting, while reinforcing the favorable efficacy and safety profile observed in five prior studies,” said Gerri Henwood, Recro Pharma’s President and Chief Executive Officer. “Given the urgent need for non-opioid pain relief alternatives, we believe the data from this trial, together with the positive data from our previously reported pivotal Phase III trial in post-surgical bunionectomy patients, completes the efficacy platform for an NDA for IV meloxicam as a new, non-opioid analgesic option for acute moderate-to-severe postoperative pain.  Enrollment in the remaining, ongoing safety study is expected to be complete by the end of the first quarter or early second quarter 2017, with an NDA filing expected to follow in summer 2017.”

The secondary endpoints of: SPID6, time to first rescue, number of subjects rescued 0-24 hours, number of subjects rescued 0-48 hours, time to meaningful pain relief, percent of subjects ≥30% improved at 6 hours, percent of subjects ≥50% improved at 6 or 24 hours, and Patient Global Assessment of pain control at 24 hours were not significantly different between treatment groups.

Recro plans to submit additional data from this Phase III clinical trial for presentation at a future scientific conference or in a journal publication.

About Abdominoplasty

Abdominoplasty surgery generally involves the removal of excess fat and skin and, in most cases, restores weakened or separated muscles from the abdominal area. According to the American Society for Aesthetic Plastic Surgery, abdominoplasty is among the top five most common cosmetic surgeries in the U.S., with more than 164,000 performed in 2014.  Abdominoplasty surgery typically results in intense postoperative pain.

About IV/IM Meloxicam

Meloxicam is a long-acting, preferential COX-2 inhibitor that possesses anti-inflammatory, analgesic, and antipyretic activities, which are believed to be related to the inhibition of cyclooxygenase (COX) and subsequent reduction in prostaglandin biosynthesis. Meloxicam has been marketed by Boehringer Ingelheim Pharmaceuticals, Inc. since the 1990’s as an oral agent, Mobic®. IV/IM meloxicam was designed using NanoCrystal® platform, a technology that enables enhanced bioavailability of poorly water-soluble drug compounds. Recro acquired IV/IM meloxicam from Alkermes in April 2015.

About Recro Pharma, Inc.

Recro Pharma is a revenue generating specialty pharmaceutical company focused on products for hospital and ambulatory care settings that is currently developing non-opioid products for the treatment of serious acute pain. Recro Pharma is currently developing IV meloxicam, a proprietary, long-acting preferential COX-2 inhibitor for treatment of acute postoperative pain, which has completed four successful Phase II clinical trials in postoperative pain conditions and has reported positive results from its two pivotal Phase III clinical trials in patients following bunionectomy surgery, and in patients following abdominoplasty surgery. An additional development candidate, Dex-IN, a proprietary intranasal formulation of dexmedetomidine, is being pursued for the treatment of peri-procedural pain, and has had a past successful Phase II trial in Bunionectomy. As Recro Pharma’s product candidates are not in the opioid class of drugs, the Company believes its candidates would avoid many of the side effects associated with commonly prescribed opioid therapeutics, such as addiction, constipation and respiratory distress, while maintaining analgesic effect.

Recro Pharma also owns and operates a 97,000 square foot, DEA-licensed facility that manufactures five commercial products and receives manufacturing revenues and royalties associated with the sales of these products.

Cautionary Statement Regarding Forward Looking Statements

Any statements in this press release about future expectations, plans and prospects for the Company, including statements about the Company’s strategy, future operations, clinical development plans and other statements containing the words “anticipate,” “believe,” “estimate,” “upcoming,” “plan,” “target”, “intend,” “expect” and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: results and timing of the clinical trials of injectable meloxicam and Dex-IN; unfavorable new clinical data and additional analyses of existing clinical data; whether results of early clinical trials will be indicative of the results of future trials and whether interim results from a clinical trial will be predictive of the final results of the trial; the ability to obtain and maintain regulatory approval of injectable meloxicam and Dex-IN, and the labeling under any such approval; regulatory developments in the United States and foreign countries; the Company’s ability to raise future financing for continued development; the Company’s ability to pay its debt; the performance of third-party suppliers and manufacturers; the Company’s ability to obtain, maintain and successfully enforce adequate patent and other intellectual property protection; the successful commercialization of injectable meloxicam and Dex-IN and other factors discussed in the Risk Factors set forth in the Company’s Annual Report on Form 10-K and Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission (SEC) and in other filings the Company makes with the SEC from time to time. In addition, the forward-looking statements included in this press release represent the Company’s views only as of the date of this press release. Important factors could cause our actual results to differ materially from those indicated or implied by forward-looking statements, and as such we anticipate that subsequent events and developments will cause our views to change. However, while we may elect to update these forward-looking statements at some point in the future, we specifically disclaim any obligation to do so. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.

CONTACT:   

Media Contact:
Argot Partners
Eliza Schleifstein
(973) 361-1546 
eliza@argotpartners.com

Investor Relations Contact:
Argot Partners
Susan Kim/Natalie Wildenradt
(212) 600-1902
susan@argotpartners.com
natalie@argotpartners.com

Recro Pharma, Inc.
Michael Celano
(484) 395 2413
mcelano@recropharma.com

$STEM Closes #Merger; Initiates Trading on #NASDAQ as $MBOT

Innovative Company is Advancing Transformational Micro-Robotic Technologies to Treat and Diagnose Various Medical Conditions

Investor Contacts:

EVC Group                          
Michael Polyviou/Doug Sherk - Investors                                        
mpolyviou@evcgroup.com; dsherk@evcgroup.com  
212-850-6020; 415-652-9100

$ACST Appoints #LindaOKeefe as #CFO

Acasti Contact:
Jan D’Alvise
Chief Executive Officer
450-686-4555
info@acastipharma.com
www.acastipharma.com

Media & Investor Contact:
Jessica Dyas
Canale Communications
619-849-5385
jessica@canalecomm.com

$NTN to Present at the 9th Annual #LDMicro @theLDMicro Main Event

CARLSBAD, CA / November 28, 2016 / NTN Buzztime, Inc. (NYSE MKT: NTN), announced it plans to present at the 9th Annual LD Micro Main Event on Wednesday, December 7th at the Luxe Sunset Boulevard Hotel in Los Angeles.

CEO Ram Krishan is scheduled to present at 5:00 pm PT. Mr. Krishnan and CFO Allen Wolff will be available for one-on-one meetings throughout the day. Interested investors should contact their LD Micro representative or Kirsten Chapman of LHA Investor Relations at Buzztime@lhai.com.

A webcast of the management’s presentation will be available live and via replay for a period of 90 days in the investor section of the company’s website.

The LD Micro Main Event is the largest independent conference for small/microcap companies and will feature 240 presenting names.

View NTN Buzztime’s profile here: http://www.ldmicro.com/profile/NTN

News Compliments of Accesswire

About NTN Buzztime

Buzztime (NYSE MKT: NTN) delivers interactive entertainment and innovative dining technology to bars and restaurants in North America. Venues license Buzztime’s customizable solution to differentiate themselves via competitive fun by offering guests trivia, card, sports and arcade games, nationwide competitions, personalized menus, and self-service dining features. Buzztime’s platform improves operating efficiencies, creates connections among the players and venues, and amplifies guests’ positive experiences. Founded in 1984, Buzztime has accumulated over 9 million player registrations and over 115 million games were played in 2015 alone. For more information, please visit http://www.buzztime.com or follow us on Facebook or Twitter @buzztime.

About LD Micro

LD Micro was founded in 2006 with the sole purpose of being an independent resource in the microcap space. What started out as a newsletter highlighting unique companies has transformed into an event platform hosting several influential conferences annually (Invitational, Summit, and Main Event).

In 2015, LDM launched the first pure microcap index (the LDMi) to exclusively provide intraday information on the entire sector. LD will continue to provide valuable tools for the benefit of everyone in the small and microcap universe.

For those interested in attending, please contact David Scher at david@ldmicro.com or visit www.ldmicro.com/events for more information.

Contact:

Kirsten Chapman/Becky Herrick, LHA Investor Relations
Email: buzztime@lhai.com
Phone: 415-433-3777

$PZRX Receives #OrphanDrug Designation from #FDA for #PRXOTC in #OTCD

On track to file investigational new drug (IND) application in late 2017

SEATTLE, Nov. 28, 2016  — PhaseRx, Inc. (NASDAQ: PZRX), a biopharmaceutical company developing mRNA treatments for life-threatening inherited liver diseases in children, today announced that its lead candidate, PRX-OTC, which is being developed for the treatment of ornithine transcarbamylase deficiency (OTCD), has received orphan drug designation by the U.S. Food and Drug Administration (FDA).

OTCD is a rare liver disorder caused by an inherited single-gene deficiency that results in hyperammonemia (elevated ammonia in the blood), and can lead to irreversible neurological impairment, coma and death. PRX-OTC is an intracellular enzyme replacement therapy (i-ERT) designed to replace the missing or defective enzyme in patients with OTCD, thereby correcting the disease. PRX-OTC has shown therapeutic potential in a preclinical model of OTCD, including lowering of blood ammonia and survival of 100% of treated mice.

“The FDA’s decision to grant PRX-OTC orphan drug designation for OTCD is another important milestone in the development of our lead product candidate, as we prepare to file the IND by the end of 2017 and initiate our clinical trial in 2018,” said Robert W. Overell, Ph.D., president and chief executive officer. “PRX-OTC is the first of three drugs in development using our Hybrid mRNA Technology™, and we believe it has the potential to correct the disease in children, a population that could particularly benefit from treatment for this rare disease. Our team at PhaseRx is driving hard to advance these drugs to help the lives of families affected by this devastating liver disease that causes irreversible brain damage and potentially fatal ammonia toxicity.”

The FDA grants orphan drug designation to investigational drugs and biologics that are intended for the treatment of rare diseases that affect fewer than 200,000 people in the U.S. Orphan drug status is intended to facilitate drug development for rare diseases and may provide several benefits to drug developers, including assistance with clinical study design and drug development, tax credits for qualified clinical trials costs, exemptions from certain FDA application fees, and seven years of market exclusivity upon regulatory product approval.

About OTCD

OTCD is a rare liver disorder typically diagnosed between birth and the age of twelve. It is caused by an inherited single-gene deficiency that results in hyperammonemia (elevated ammonia in the blood), and can lead to devastating consequences, including cumulative and irreversible neurological impairment, coma and death. The only cure for OTCD is a liver transplant. Currently available drug treatments do not correct the disease, and do not eliminate the risk of life-threatening crises.

About PhaseRx

PhaseRx is a biopharmaceutical company dedicated to developing mRNA products for the treatment of children with inherited enzyme deficiencies in the liver using intracellular enzyme replacement therapy (i-ERT). PhaseRx’s initial product development focus is on urea cycle disorders, a group of rare genetic diseases that generally present before the age of twelve and are characterized by the body’s inability to remove ammonia from the blood with potentially devastating consequences for patients. The company’s i-ERT approach is enabled by its proprietary Hybrid mRNA Technology™ platform. PhaseRx is headquartered in Seattle. For more information, please visit www.phaserx.com.

Safe Harbor Statement

This press release contains “forward-looking statements.” Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the company’s control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) the fact that the company has incurred significant losses since its inception and anticipates that it will continue to incur significant losses for the foreseeable future, (ii) the company being dependent on technologies it has licensed and that it may need to license in the future to develop its products, (iii) the fact that the company will need to raise substantial additional funding to bring its planned products through clinical trials, regulatory approval, manufacturing and marketing and to become profitable, (iv) the fact that the company’s Hybrid mRNA Technology has not previously been tested beyond company preclinical studies, and that mRNA-based drug development is unproven and may never lead to marketable products, (v) the fact that all of the company’s programs are in preclinical studies or early stage research, so the company cannot predict how these results will translate into results in humans, nor can it be certain that any company product candidates will receive regulatory approval or be commercialized, (vi) the fact that development of the company’s product candidates will be expensive and time-consuming, and if the development of company product candidates does not produce favorable results or is delayed, the company may be unable to commercialize these products, (vii) the company expecting to continue to incur significant research and development expenses, which may make it difficult to attain profitability, (viii) the company becoming dependent on collaborative arrangements with third parties for a substantial portion of its revenue, and its development and commercialization activities being delayed or reduced if it fails to initiate, negotiate or maintain successful collaborative arrangements, (ix) the company’s ability to adequately protect its proprietary technology from legal challenges, infringement or alternative technologies and (x) the biotechnology and pharmaceutical industries being intensely competitive, with competition from existing drugs, new treatment methods and new technologies that may prove to be more effective or marketable than the company’s products. More detailed information about the company and the risk factors that may affect the realization of forward looking statements is set forth in the company’s filings with the Securities and Exchange Commission (SEC), including the company’s prospectus filed pursuant to Rule 424(b) under the Securities Act of 1933, as amended, with the SEC on May 23, 2016. Investors and security holders are urged to read these documents free of charge on the SEC’s web site at http://www.sec.gov. The company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.

Contacts: 

Company Contact:
Erin S. Cox
PhaseRx, Inc.
Director of Investor Relations
erin@phaserx.com
206.805.6306

Corporate Communications Contact:
Jason Spark
Canale Communications
Senior Vice President
jason@canalecomm.com
619.849.6005

Investor Contact:
Robert H. Uhl
Westwicke Partners, LLC
Managing Director
robert.uhl@westwicke.com
858.356.5932

$MTFBW Closes $25 Million #IPO & #EU Placement

NEW YORK, Nov. 23, 2016 — Motif Bio plc (Motif) (NASDAQ:MTFB), (NASDAQ:MTFBW), a clinical stage biopharmaceutical company specializing in developing novel antibiotics, announced today the closing of its initial U.S. public offering of approximately 2.44 million American Depositary Shares (ADSs) with 50% warrant coverage. Each ADS, representing 20 ordinary shares of Motif, and warrant to purchase 0.5 ADSs were sold at a price to the public of $6.98 per ADS and warrant combination.  Motif has granted the underwriters a 30-day option to purchase up to an additional 292,618 ADSs and/or 146,309 warrants to cover over-allotments, if any, in the U.S. offering.

Each full ADS warrant has a per ADS exercise price of $8.03. The ADS warrants are exercisable immediately and have a term of five years. The ADSs and ADS warrants are listed on The NASDAQ Capital Market under the symbols “MTFB” and “MTFBW,” respectively.

H.C. Wainwright & Co., LLC acted as the sole book-running manager for the offering.

Motif also closed its concurrent placement in Europe of approximately 22.9 million ordinary shares with 50% warrant coverage. Each ordinary share and warrant to purchase 0.5 of an ordinary share were sold at a price to the public of 28 pence per ordinary share and warrant combination. Each full ordinary share warrant has a per ordinary share exercise price of 32.2 pence.  The ordinary share warrants are exercisable immediately and have a term of five years.  Motif’s ordinary shares trade on the AIM market of the London Stock Exchange under the ticker symbol “MTFB.”

Zeus Capital Limited, Northland Capital Partners and MC Services acted as the placing agents in the European Placement.

The aggregate gross proceeds to the Company, before deducting underwriting discounts and commissions, placing agent commissions and other estimated offering expenses, were approximately $25 million.

The Company intends to use the net proceeds from these offerings, together with cash and cash equivalents on hand, (i) to fund the expenses to be incurred in conducting the two Phase 3 clinical trials of iclaprim for the treatment of ABSSSI, including the completion of our REVIVE-1 trial; and (ii) for working capital, general and administrative expenses, research and development expenses, and other general corporate purposes.

While the Board believes that, along with the Company’s existing cash and cash equivalents, the net proceeds from the U.S. offering and concurrent European placement will provide sufficient capital to enable the Company to complete the REVIVE-1 trial, the Company will require additional funds to complete the REVIVE-2 trial and plans to raise the additional capital through public or private financings and/or other partnering opportunities.

The registration statement relating to these securities was declared effective by the U.S. Securities and Exchange Commission on November 17, 2016. The U.S. offering is being made only by prospectus. Copies of the final prospectus related to the offering may be obtained from: H.C. Wainwright & Co., 430 Park Avenue, New York, NY 10022, telephone: 212-356-0500, or e-mail: placements@hcwco.com. Investors may also obtain these documents at no cost by visiting the SEC’s website at http://www.sec.gov.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Motif

Motif Bio is a clinical-stage biopharmaceutical company, engaged in the research and development of novel antibiotics designed to be effective against serious and life-threatening infections in hospitalized patients caused by multi-drug resistant bacteria. Our lead product candidate, iclaprim, is being developed for the treatment of acute bacterial skin and skin structure infections (ABSSSI) and hospital acquired bacterial pneumonia (HABP), including ventilator associated bacterial pneumonia (VABP), which is often caused by MRSA (methicillin resistant Staphylococcus aureus). We are currently enrolling and dosing patients in two global Phase 3 clinical trials (REVIVE-1 and REVIVE-2) with an intravenous formulation of iclaprim, for the treatment of ABSSSI.  Data readout for REVIVE-1 is expected in the second quarter of 2017 and REVIVE-2 is on track for data readout in the second half of 2017.

For further information please contact:

Motif Bio plc Contact:
Pete A. Meyers
Chief Financial Officer
212-210-6248
ir@motifbio.com

Investor Contact:
Patricia L. Bank
Westwicke Partners
415-513-1284
patti.bank@westwicke.com

$XBIO to Host #Quarterly Update #ConferenceCall and #Webcast

Xenetic Biosciences, Inc. (NASDAQ: XBIO) (“Xenetic” or the “Company”), a clinical-stage biopharmaceutical company focused on the discovery, research and development of next-generation biologic drugs and novel orphan oncology therapeutics, announced today that the Company’s management team will host a quarterly update conference call with a live webcast for investors, analysts and other interested parties.

During the conference call, the Company will provide a corporate update and discuss the clinical and regulatory progress for its in-house product candidates, as well as those being developed with Xenetic’s biotechnology and pharmaceutical partners. Xenetic’s current in-house product pipeline includes Virexxa^® (sodium cridanimod), which is being evaluated for the treatment of endometrial cancer and triple negative breast cancer, and ErepoXen™, a polysialylated form of erythropoietin (EPO), a hormone created by the kidneys to maintain red blood cell production and prevent anemia. Xenetic is also currently evaluating OncoHist™ for the treatment of acute myeloid leukemia (AML) in refractory patients and refractory non-Hodgkin lymphoma (NHL).

Conference Call and Webcast Information

Xenetic management will host a conference call for investors, analysts and other interested parties on Wednesday, November 30, 2016 at 8:30 a.m. ET. The conference call and live webcast will be accompanied by presentation slides.

To participate in the call, please dial (877) 407-6914 (domestic) or (201) 493-6709 (international). The live webcast and accompanying slides will be available by accessing the IR Calendar in the Investors section of Xenetic’s website (www.xeneticbio.com). A replay of the webcast will be available for 90 days, starting approximately two hours after the presentation ends.

About Xenetic Biosciences

Xenetic Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on discovery, research and development of next-generation biologic drugs and novel oncology therapeutics. Xenetic’s proprietary drug technology platforms include PolyXen®, designed to develop next generation biologic drugs by extending the efficacy, safety and half-life of biologic drugs.

Xenetic’s lead investigational product candidates include ErepoXen™, a polysialylated form of erythropoietin for the treatment of anemia in pre-dialysis patients with chronic kidney disease, and FDA orphan designated oncology therapeutics Virexxa™ and Oncohist™ for the treatment of progesterone receptor negative endometrial cancer and refractory Acute Myeloid Leukemia.

Xenetic is also working together with Shire plc (formerly Baxalta, Baxter Incorporated and Baxter Healthcare) to develop a novel series of polysialylated blood coagulation factors, including a next generation Factor VIII. This collaboration relies on Xenetic’s PolyXen technology to conjugate polysialic acid (“PSA”) to therapeutic blood-clotting factors, with the goal of improving the pharmacokinetic profile and extending the active life of these biologic molecules. Shire is one of the Company’s largest shareholders having invested $10M in the common stock of the Company during 2014. The agreement is an exclusive research, development and license agreement which grants Shire a worldwide, exclusive, royalty-bearing license to Xenetic’s PSA patented and proprietary technology in combination with Shire’s proprietary molecules designed for the treatment of blood and bleeding disorders. Under the agreement, Xenetic may receive regulatory and sales target payments for total potential milestone receipts of up to $100 million plus royalties on sales.

Xenetic is also developing a broad pipeline of clinical candidates for next generation biologics and novel oncology therapeutics in a number of orphan disease indications. For more information, please visit the company’s website at www.xeneticbio.com and connect on Twitter, LinkedIn, Facebook and Google+.

Forward-Looking Statements

This press release contains “forward-looking statements,” as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA), which statements may be identified by words such as “expects,” “plans,” “projects,” “will,” “may,” “anticipates,” “believes,” “should,” “intends,” “estimates,” and other words of similar meaning, including statements regarding expected benefits of NGS cancer panels, the ability to accurately determine the heritable factors increasing the risk of cancer, permitting tailored treatment, screening and prevention of cancer in patients, as well as other non-historical statements about our expectations, beliefs or intentions regarding our business, technologies and products, financial condition, strategies or prospects. Many factors could cause our actual activities or results to differ materially from the activities and results anticipated in forward-looking statements. These factors include those described in our filings with the Securities and Exchange Commission, as well as the risks inherent in funding, developing and obtaining regulatory approvals of new, commercially-viable and competitive products and treatments. In addition, forward-looking statements may also be adversely affected by general market factors, competitive product development, product availability, federal and state regulations and legislation, the regulatory process for new products and indications, manufacturing issues that may arise, patent positions and litigation, among other factors. The forward-looking statements contained in this press release speak only as of the date the statements were made, and we do not undertake any obligation to update forward-looking statements. We intend that all forward-looking statements be subject to the safe-harbor provisions of the PSLRA.

$GLBS Announces the Appointment of a New Non Executive Director

$ESEA Announces the Acquisition of a #Drybulk #Vessel and Short-term Loan Facility

$OPCO among Public Company Executives to Present Online to Investors on December 1

VirtualInvestorsConferences.com hosts CEOs & CFOs: live questions answered during online roadshow and in virtual trade booths

NEW YORK, Nov. 23, 2016  — PR Newswire and BetterInvesting (NAIC) today announced the agenda for the upcoming VirtualInvestorConferences.com, the evergreen online investor conference series. Individual investors, institutional investors, advisors, and analysts are invited. The show opens on at 9:00 AM ET, with the first live webcast at 9:15 AM ET, on Thursday, December 1.

REGISTER NOW: http://tinyurl.com/1201agenda

Pre-registration is suggested to save time: There is no fee for anyone to log-in, attend the live presentations and ask questions.

December 1 Agenda:

Learn More about the Event: To facilitate investor relations scheduling and budgeting, more information, including a full calendar of VirtualInvestorConferences.com dates is available at: http://virtualinvestorconferences.com

About VirtualInvestorConferences.com

VirtualInvestorConferences.com, created by BetterInvesting (NAIC) and PRNewswire, has been the only monthly virtual investor conference series that provides an interactive forum for presenting companies to meet directly with investors using a graphically-enhanced online platform.

Designed to replicate the look and feel of location-based investor conferences, Virtual Investor Conferences unites PR Newswire’s leading-edge online conferencing and investor communications capabilities with BetterInvesting’s extensive retail investor audience network.

$ISDR to Present at the 9th Annual #LDMicro Main Event

Issuer Direct’s Accesswire News Platform to Sponsor LD Micro’s 9th Annual Main Event

MORRISVILLE, NC / November 22, 2016 / Issuer Direct Corporation (ISDR), (the “Company”), a market leader and innovator of disclosure management solutions and targeted communications today announced that its Founder and Chief Executive Officer, Brian R. Balbirnie will be presenting at the 9th Annual LD Micro Main Event on Tuesday, December 6th at 9:00 AM PST / 12:00 PM EST at the Luxe Sunset Boulevard Hotel in Los Angeles, CA.

The LD Micro Main Event is the largest independent conference for small/microcap companies and will feature 240 presenting names.

View Issuer Direct’s profile here: http://www.ldmicro.com/profile/ISDR

News Compliments of Accesswire

About Issuer Direct Corporation

Issuer Direct® is a disclosure management and targeted communications company. Our integrated platform provides tools, technologies and services that enable our clients to disclose and disseminate information through our network. With a focus on corporate issuers, the Company alleviates the complexity of maintaining compliance with its integrated portfolio of products and services that enhance companies’ ability to efficiently produce and distribute their financial and business communications both online and in print.

About LD Micro

LD Micro was founded in 2006 with the sole purpose of being an independent resource in the microcap space. What started out as a newsletter highlighting unique companies has transformed into an event platform hosting several influential conferences annually (Invitational, Summit, and Main Event).

In 2015, LDM launched the first pure microcap index (the LDMi) to exclusively provide intraday information on the entire sector. LD will continue to provide valuable tools for the benefit of everyone in the small and microcap universe.

For those interested in attending, please contact David Scher at david@ldmicro.com or visit www.ldmicro.com/events for more information.

Learn more about Issuer Direct today: Investor Tear Sheet.

Forward-Looking Statements. This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) (which Sections were adopted as part of the Private Securities Litigation Reform Act of 1995). Statements preceded by, followed by or that otherwise include the words “believe,” “anticipate,” “estimate,” “expect,” “intend,” “plan,” “project,” “prospects,” “outlook,” and similar words or expressions, or future or conditional verbs such as “will,” “should,” “would,” “may,” and “could” are generally forward-looking in nature and not historical facts. These forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the Company’s actual results, performance or achievements to be materially different from any anticipated results, performance or achievements. The Company disclaims any intention to, and undertakes no obligation to, revise any forward-looking statements, whether as a result of new information, a future event, or otherwise. For additional risks and uncertainties that could impact the Company’s forward-looking statements, please see the Company’s Annual Report on Form 10-K for the year ended December 31, 2015 including but not limited to the discussion under “Risk Factors” therein, which the Company has filed with the SEC and which may be viewed at http://www.sec.gov/.

For Further Information:

Issuer Direct Corporation
Brian R. Balbirnie
(919)-481-4000
brian.balbirnie@issuerdirect.com

Hayden IR
Brett Maas
(646)-536-7331
brett@haydenir.com

Hayden IR
James Carbonara
(646)-755-7412
james@haydenir.com

$FATE Announces Private Financing

SAN DIEGO, Nov. 22, 2016  — Fate Therapeutics, Inc. (NASDAQ:FATE), a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, today announced that it has entered into a definitive securities purchase agreement with certain institutional and other accredited investors. The private placement is being led by Redmile Group LLC with participation from BVF Partners L.P., EcoR1 Capital LLC and Franklin Advisers, Inc. as well as certain individual investors including members of the Company’s Board of Directors. Gross proceeds from the private placement are expected to be approximately $57 million dollars.

Redmile has agreed to purchase 2,819,549 shares of non-voting Class A Preferred Stock at $13.30 per share, each of which is convertible into five shares of common stock upon certain conditions. The remaining investors have agreed to purchase 7,236,837 shares of common stock at $2.66 per share. The purchase and sale is expected to close on or about November 23, 2016, subject to customary closing conditions.

The Company expects to use the proceeds from the transaction primarily to advance its pipeline of programmed cellular immunotherapies and for general corporate purposes. Leerink Partners LLC acted as the exclusive placement agent to the Company in connection with the private financing.

The offer and sale of the foregoing securities are being made in a transaction not involving a public offering and have not been registered under the Securities Act of 1933, as amended (the Securities Act), or applicable state securities laws. Accordingly, the securities may not be reoffered or resold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act and such applicable state securities laws. As part of the transaction, the Company has agreed to file a registration statement with the Securities and Exchange Commission for purposes of registering the resale by the investors not affiliated with the Company of the shares of common stock purchased by such investors.

This press release is issued pursuant to Rule 135(c) under the Securities Act of 1933, as amended, and does not constitute an offer to sell or the solicitation of an offer to buy the securities, nor shall there be any sale of the securities in any state in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of such state. Any offering of the securities under the resale registration statement will only be by means of a prospectus.

About Fate Therapeutics, Inc.
Fate Therapeutics is a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders. The Company’s hematopoietic cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf product candidates derived from engineered induced pluripotent cells, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients undergoing hematopoietic cell transplantation and to promote immune tolerance in patients with autoimmune disease. Its adoptive cell therapy programs are based on the Company’s novel ex vivo cell programming approach, which it applies to modulate the therapeutic function and direct the fate of immune cells. Fate Therapeutics is headquartered in San Diego, CA. For more information, please visit www.fatetherapeutics.com.

Forward-Looking Statements
This release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the timing of the consummation of the private placement and the expected receipt and use of proceeds from the private placement. These and any other forward-looking statements in this release are based on management’s current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, the risk that the closing conditions for the private placement transaction are not met by the expected closing date or at all, the risk that the resale registration statement covering the common stock is not timely filed by the Company or declared effective by the Securities and Exchange Commission (SEC), the risk that the Company may not use the proceeds from the private placement as currently expected, the risk that the Company may cease or delay preclinical or clinical development activities for any of its existing or future product candidates for a variety of reasons (including difficulties or delays in patient enrollment in current and planned clinical trials), and the risk that the Company may not be able to raise the additional funding required for its business and product development plans. For a discussion of other risks and uncertainties, and other important factors, any of which could cause our actual results to differ from those contained in the forward-looking statements, see the risks and uncertainties detailed in the Company’s periodic filings with the Securities and Exchange Commission, including but not limited to the Company’s most recently filed periodic report, and from time to time the Company’s other investor communications. Fate Therapeutics is providing the information in this release as of this date and does not undertake any obligation to update any forward-looking statements contained in this release as a result of new information, future events or otherwise.

Contact:
Christina Tartaglia
Stern Investor Relations, Inc.
212.362.1200
christina@sternir.com

$PME Announces Commencement of Fishing Activity in Indo-Pacific Waters

FUZHOU, China, Nov. 22, 2016  —

The Company rebuilt approximately 20% of its production capacity

Pingtan Marine Enterprise Ltd. (Nasdaq: PME) (“Pingtan,” or the “Company”), a global fishing company based in the People’s Republic of China (PRC), today announced that thirteen of its fishing vessels have arrived in the harvesting areas of Indo-Pacific waters.

These thirteen fishing vessels were placed in Indo-Pacific waters according to the Company’s previously announced operating plan in August 2016, and have recently arrived in their fishing designation in Indo-Pacific Waters to be put into operation.  The Company expects to begin recognizing sales from this expansion in the current fourth quarter of 2016.

Pingtan currently owns one hundred thirty five fishing vessels, twelve of which are operating in the Bay of Bengal in India along with these thirteen vessels in Indo-Pacific Waters. As of today, the Company’s twenty five fishing vessels are fully operating and have rebuilt approximately 20% of its production capacity. In accordance with the Company’s previous results of 2014, each of its fishing vessels can generate annual revenue of approximately $3 million USD with annual net income of approximately $800,000 to $1 million.

Mr. Xinrong Zhuo, Chairman and CEO of the Company, commented, “We are very pleased to begin fishing activities in the bountiful Indo-Pacific Waters, and utilizing our assets and advantages to meet the continued demand in China. We remain dedicated to actively seeking new water territories where we can expand, increasing our production and provide high quality fishing products to our customers.”

About Pingtan

Pingtan is a global fishing company engaging in ocean fishing through its wholly-owned subsidiary, Fujian Provincial Pingtan County Ocean Fishing Group Co., Ltd., or Pingtan Fishing.

Business Risks and Forward-Looking Statements

This press release may contain forward-looking statements that are subject to the safe harbors created under the Securities Act of 1933 and the Securities Exchange Act of 1934, including statements that the Company expects to begin recognizing sales from the expansion of its fishing operations in the Indo-Pacific Waters in the fourth quarter of 2016. In addition, please refer to the risk factors contained in Pingtan’s SEC filings available at www.sec.gov, including Pingtan’s most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and Definitive Proxy Statement. Readers are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date on which they are made. Pingtan undertakes no obligation to update or revise any forward-looking statements for any reason.

CONTACT:

Roy Yu
Chief Financial Officer
Pingtan Marine Enterprise Ltd.
Tel: +86 591 87271753
ryu@ptmarine.net

INVESTOR RELATIONS

The Equity Group Inc.
Adam Prior, Senior Vice President
Tel: (212) 836-9606
aprior@equityny.com

In China

Katherine Yao, Senior Associate
Tel: +86 10 6587 6435
kyao@equityny.com

$KALV Announces Closing of #Merger with #CarbylanTherapeutics

—Combined company renamed KalVista Pharmaceuticals, Inc., listed on Nasdaq with ticker “KALV” —

—Continued focus on development of protease inhibitors with multiple molecules for oral treatment of hereditary angioedema (HAE) in the clinic in 2017—

—Appoints Benjamin L. Palleiko as Chief Financial Officer—

CAMBRIDGE, Mass. and PALO ALTO, Calif., Nov. 22, 2016  — KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today announced the closing of the previously announced merger with Carbylan Therapeutics, Inc. As a result of the completion of this transaction, Carbylan changed its name to KalVista Pharmaceuticals, Inc. The Company will commence trading on November 22, 2016 on the NASDAQ Stock Market under the symbol “KALV”.

KalVista is now funded with more than $38 million to support its portfolio of drug development programs, initially focused on oral plasma kallikrein treatments for hereditary angioedema (HAE) and diabetic macular edema (DME). KalVista is developing a portfolio of drugs for HAE, with the first oral HAE candidate, KVD818, having commenced a Phase I clinical trial in the third quarter of 2016.  Additional HAE candidates are planned to begin clinical trials in 2017 and beyond.  KalVista’s objective is to advance multiple oral drug candidates through Phase I, first-in-human studies in order to select those with the potential to deliver best-in-class status for further development.  KalVista is also developing KVD001, an intravitreally-delivered therapy for DME.  This program has completed a Phase I clinical trial in DME patients and is expected to progress to Phase II clinical development in 2017.

In conjunction with the closing, KalVista welcomed Benjamin L. Palleiko as the Chief Financial Officer of KalVista. Mr. Palleiko has over twenty years of experience in the industry, as both a senior life sciences investment banker and Chief Financial Officer of several public and private life sciences companies. He has raised more than $2 billion in capital and completed over 50 transactions in his business career. Mr. Palleiko holds a MBA in Finance and a MA in International Relations from the University of Chicago, and a BA in Quantitative Economics from Tufts University. Prior to graduate school, he served in the U.S. Navy as a Naval Aviator flying carrier-based jet aircraft.

“The transition of KalVista to the public markets is an important milestone in the strategic development of the Company as we advance our pipeline of novel serine protease therapeutics,” said Andrew Crockett, KalVista’s Chief Executive Officer. “With the capital raised in this transaction and an experienced leadership team, KalVista is even better positioned to accelerate our clinical programs to bring new treatment options to patients with hereditary angioedema and diabetic macular edema. We also are particularly pleased that Ben Palleiko has chosen to join us as CFO at this time, as his deep background and skills will help us as we enter the next phase of growing shareholder value as a public company.”

The executive leadership of the new Company is comprised of members of the KalVista management team, with members of the Carbylan team departing the Company. The management team is initially comprised of Mr. Crockett as Chief Executive Officer; Christopher Yea, Ph.D. as Chief Development Officer; and Mr. Palleiko as Chief Financial Officer. The board of directors is comprised of seven members, consisting of five members designated by KalVista: Richard Aldrich, who will serve as Chairman, Joshua Resnick, M.D., Rajeev Shah, Edward W. Unkart and Mr. Crockett; and two members designated by Carbylan, Albert Cha, M.D., Ph.D, and Arnold L. Oronsky, Ph.D. The Company has offices in Cambridge, MA and Porton Down, U.K.

About Hereditary Angioedema (HAE)
Hereditary angioedema (HAE) is a rare and potentially life-threatening genetic condition that occurs in fewer than 1 in 10,000 people. HAE patients are susceptible to sudden and prolonged attacks of edema, which often occur in the hands, feet, face, gastrointestinal tract, and airway. Attacks can result in severe swelling and pain, airway blockage, and nausea.

About Diabetic Macular Edema (DME)
Diabetic Macular Edema (DME) is a sight-threatening disease caused by disruption of the blood/retinal barrier leading to the accumulation of fluid in the macula and vision loss. DME affects an estimated 16% of diabetic patients within their lifetime, according to a 2012 study published in Diabetes Care. Approximately 900,000 patients in the United States alone have active DME and are at serious risk of vision loss, according to a 2013 study.

About KalVista Pharmaceuticals, Inc.
KalVista Pharmaceuticals, Inc. is a pharmaceuticals company focused on the discovery, development, and commercialization of small molecule protease inhibitors for diseases with significant unmet need. The initial focus is on inhibitors of plasma kallikrein, which is an important component of the body’s inflammatory response, and which in excess can lead to increased vascular permeability, edema and inflammation. KalVista has developed a proprietary portfolio of novel, small molecule plasma kallikrein inhibitors initially targeting hereditary angioedema (HAE) and diabetic macular edema (DME). The Company has created a structurally diverse portfolio of oral plasma kallikrein inhibitors from which it plans to select multiple drug candidates to advance into clinical trials for HAE. In August 2016, KalVista commenced a Phase I first-in-human clinical trial for KVD818, the first of its orally delivered molecules for the treatment of HAE. KalVista’s most advanced program, an intravitreally administered plasma kallikrein inhibitor known as KVD001, has successfully completed its first‑in‑human study in patients with DME and is being prepared for Phase 2 studies in 2017.

For more information, please visit www.KalVista.com.

Forward-Looking Statements
This press release contains “forward-looking” statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: “anticipate,” “intend,” “plan,” “goal,” “seek,” “believe,” “project,” “estimate,” “expect,” “strategy,” “future,” “likely,” “may,” “should,” “will” and similar references to future periods. These statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from what we expect. Examples of forward-looking statements include, among others, future clinical trial timing and results. Further information on potential risk factors that could affect our business and its financial results are detailed in the definitive proxy statement filed on October 28, 2016, our most recent Quarterly Report on Form 10-Q, and other reports as filed from time to time with the Securities and Exchange Commission. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

Contact:
KalVista Pharmaceuticals
Leah Monteiro, Corporate Communications
857-241-3897
lmm@KalVista.com

$NETE Partners with #Mashreqbank in #UAE, #Fintech #Transactional #PaaS

Payment gateway processing agreement with leading UAE financial institution expands Net Element’s processing capabilities in the region

$ABIL Announces Nomination of Three New Independent Directors

Major General (Ret.) Amos Malka, Amnon Dick, and Shalom Singer Will Bring Experience and Proven Strategic Counsel to Ability’s Board of Directors

TEL AVIV, Israel, Nov. 21, 2016  — Ability, Inc. (NASDAQ/TASE: ABIL), a leading provider of innovative tactical communications intelligence solutions, today announced that three highly experienced directors have been nominated for election to its Board of Directors at its upcoming annual meeting scheduled to be held on December 19, 2016.

Anatoly Hurgin, the Company’s Chief Executive Officer, stated, “As Ability continues to evolve, increasingly focused on our disruptive ULIN technology, we believe this newly reconstituted Board with its proven experience and deep industry connections is best equipped to help us deliver on Ability’s potential and enhance the Company’s sustainable, long-term value.” Mr. Hurgin continued, “That such experienced and respected directors have agreed to join Ability’s Board is a clear vote of confidence in the Company. I am certain that the seasoned professionals we have nominated to the Board will help guide the Company by providing unique solutions to help governments and law enforcement agencies overcome challenges related to crime and terrorism.  On behalf of the Company, I thank Benjamin Gordon, Mitchell I. Gordon and Derek Zissman for their service to the Company.”

The new nominees for election as directors are:

• Maj. Gen. (Ret.) Amos Malka, the former Head of the Israeli Defense Intelligence and Commander of the Israel Defense Forces Ground Forces Command, is a preeminent expert in national strategy, intelligence, homeland security, counter terrorism and cyber security. Mr. Malka currently serves as the chairman of the board of directors of TAT Technologies Ltd., whose shares are listed on both the Tel Aviv Stock Exchange (“TASE”) and NASDAQ. Mr. Malka is the founder and chairman of Nyotron Information Security Ltd., a privately-held cyber security provider based in Israel and Silicon Valley. Mr. Malka is also the founder and owner of Spire Security Solutions, a strategic consulting firm. Mr. Malka holds a B.A. in history from Tel Aviv University and is a graduate of the IDF Staff and Command College and the Israel National Defense Academy. Upon his election to Ability’s Board of Directors, Mr. Malka is expected to serve on the Board’s Compensation Committee.
• Amnon Dick currently serves as a member of each of the board of directors, corporate governance committee and remuneration committee of Bank Hapoalim, Israel’s largest bank. From 2003 to 2005, Mr. Dick served as the chief executive officer of Bezeq The Israel Telecommunications Corp. Ltd. (“Bezeq”), Israel’s largest telecommunications provider. In his role as CEO, Mr. Dick led the formerly state-owned Bezeq through one of the most important and complex privatizations in the history of the Israeli economy. From 1994 to 2003, Mr. Dick served on each of the board of directors and the audit committee of Israel Chemicals Ltd., a multinational chemicals manufacturer. From 1997 to 2001, Mr. Dick served as the chairman and Chief Executive Officer of Elite International, a major player in the global coffee industry (today part of Strauss Group Ltd.). From 1993 to 1995, Mr. Dick served as the Chief Executive Officer of Jafora-Tabori Ltd., a leading beverage company. Mr. Dick started his career at Coca-Cola Israel, where he held several senior leadership positions. Mr. Dick received his undergraduate degree in economics from Tel-Aviv University and an M.B.A. from Tel-Aviv University. Upon his election to Ability’s Board of Directors, Mr. Dick is expected to serve as its Chairman. Mr. Dick is also expected to serve on each of the Audit and Compensation Committees of the Board.
• Shalom Singer currently serves as the Managing Partner of Singer Meister Ltd., private market advisors. Mr. Singer is also the chairman and has 26% shareholding in Robert Marcus Loss Adjusters Ltd., one of the largest loss adjusters firms in Israel. Mr. Singer also serves as a member of each of the board of directors, the audit committee and the financial statements committee of TASE-listed Hadera Paper Ltd., a leading manufacturer of paper and paper-related products in Israel. From 2006 to 2008, Mr. Singer served as the chairman of the investment committee of profit participating policies at Clal Insurance Company Ltd., one of the leading insurance and pension companies in Israel. Between 2003 and 2005, Mr. Singer served as the chairman of the board of directors and chief executive officer of Kagam Central Pension Fund. Between 1999 and 2002 Mr. Singer served as executive vice chairman of the board of directors of Elbit Imaging Ltd., whose shares are listed on NASDAQ and the TASE. Mr. Singer has also served on each of the board of directors and financial statements committees of the following TASE-listed companies: Scope-Ex Metal Trading & Technical Services Ltd. (2006-2015); Scailex Corporation Ltd. (2006-2014), where he was also a member of the audit committee; and Israel Petroleum Enterprises Ltd. (2005-2015), where he was also a member of the audit committee. From 1991 to 1992, Mr. Singer served as the Director General of the Israeli Ministry of Finance. Between 1986 and 1990, Mr. Singer also served as chief executive officer of First International Bank of Israel, a TASE-listed company and the fifth largest bank in Israel. Mr. Singer also served as the chairman of the Association of Banks in Israel and was a member of the Bank of Israel Advisory Committee for Banking Affairs and the Government-held Companies Authority Advisory Committee. Mr. Singer also represented Israel’s Ministry of Finance in his service on the board of directors of Israel Chemicals Ltd. Mr. Singer is a graduate of the Faculty of Accountancy at Haifa University. Upon his election to Ability’s Board of Directors, Mr. Singer is expected to serve as the chairman of the Board’s Compensation Committee and as a member of each of the Audit and Nominating Committees.

The new nominees are expected to replace current Board members Benjamin Gordon, Mitchell I. Gordon and Derek Zissman, who will serve out the end of their terms until the upcoming annual meeting.  Following their election to the Board of Directors at the Company’s upcoming annual meeting, Messrs. Malka, Dick and Singer will join Anatoly Hurgin, the Chief Executive Officer and Chairman of Ability’s Board of Directors, Alexander Aurovsky, Ability’s Chief Technology Officer, Efraim Halevy, and Meir Moshe on Ability’s Board of Directors. Messrs. Hurgin and Aurovsky have indicated that they intend to vote their shares, representing approximately 65% of the Company’s issued and outstanding common stock, for the election of Messrs. Malka, Dick and Singer as well as the other director nominees to the Board.  Following the Company’s annual meeting, Ability’s Board of Directors will remain at seven members, five of whom will qualify as “independent” pursuant to the NASDAQ listing rules.

About Ability, Inc.

Ability, Inc. (“Ability” or the “Company”) is the sole owner of Ability Computer & Software Industries Ltd., following the December 2015 closing of the business combination between Cambridge Capital Acquisition Corporation, Ability Computer & Software Industries Ltd. and Ability.

Headquartered in Tel Aviv, Israel, Ability Computer & Software Industries Ltd. was founded in 1994. Ability provides advanced interception, geolocation and cyber intelligence tools used by security and intelligence agencies, military forces, law enforcement and homeland security agencies worldwide. Governments and government agencies in over 50 countries have used Ability’s cutting-edge technology.  Ability offers a broad range of lawful interception, decryption, cyber and geolocation solutions for cellular and satellite communication, including ULIN, or Ultimate Interception, the first-to-market SaaS strategic interception system with voice, text and geolocation capabilities without geographic limitation. State-of-the-art technology underpins Ability’s scalable offerings, which can be tactical-and-portable, or strategic-and-fixed, depending on its customers’ needs. Additional information regarding Ability may be found at http://www.interceptors.com.

Caution Regarding Forward-Looking Statements

This press release contains “forward-looking statements.” Words such as “may,” “should,” “could,” “would,” “predicts,” “potential,” “continue,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates,” and similar expressions, as well as statements in the future tense, often signify forward-looking statements. Forward-looking statements should not be read as a guarantee of future performance or results and may not accurately indicate when such performance or results will be achieved. Forward-looking statements are based on information available to the Company when such statements are made or management’s good faith belief with respect to future events as of the time such statements are made, and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in or suggested by the forward-looking statements. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.

Investor Relations Contacts:
Hayden/ MS-IR LLC
Miri Segal
Tel: +917-607-8654
E-mail: msegal@ms-ir.com
or
Brett Maas
Tel: 646-536-7331
brett@haydenir.com

$FSNN #Cloud Solutions Selected by Leading University on East Coast

Three-Year, $325,000 Contract Reflects Success of Specialized Cloud Solutions for the Higher Education Vertical Market

NEW YORK, NY–(November 21, 2016) – Fusion (NASDAQ: FSNN), a leading provider of cloud services, today announced that it has been selected to provide its single source integrated cloud solutions to support the growth requirements of a leading private university located on the East Coast. The university reviewed a number of premise-based as well as cloud-based options and chose Fusion for its cost-effective cloud voice, contact center, connectivity and business continuity solutions. The three-year, $325,000 contract reflects the success of Fusion’s targeted cloud solutions for the education vertical market.

The university cited the benefits of the Fusion cloud for its selection, including the elimination of up-front capital costs and end of life technology concerns. It further recognized the cost efficiencies of a reduction in space, IT support staff and ongoing maintenance costs made possible by the cloud, combined with an advanced feature set with business continuity built in. The university acknowledged the advantages of Fusion’s single source solution, with cloud connectivity ensuring quality of service and the end of finger pointing with one contract, one contact and one invoice.

“We appreciate the opportunity to support the university with our award-winning communications solution, including collaboration and contact center functionality, as well as connectivity over our robust, diverse national network, with automatic failover ensuring continuity of service,” said Russell P. Markman, Fusion’s President of Business Services. “The university is committed to continuous innovation and leveraging emerging technologies in support of its mission to prepare generations of students for a future as change agents. That is why as a technology company, we are especially pleased to have earned this respected institution’s business.”

About Fusion

Fusion, a leading provider of integrated cloud solutions to small, medium and large businesses, is the industry’s single source for the cloud. Fusion’s advanced, proprietary cloud service platform enables the integration of leading edge solutions in the cloud, including cloud communications, contact center, cloud connectivity, and cloud computing. Fusion’s innovative, yet proven cloud solutions lower our customers’ cost of ownership, and deliver new levels of security, flexibility, scalability and speed of deployment. For more information, please visit www.fusionconnect.com.

Fusion Contact
Brian Coyne
212-201-2404
Email contact

Darrow Associates Contacts for Fusion
Jordan Darrow
(512) 551-9296
Email contact

Bernie Kilkelly
(516) 236-7007
Email contact

$MVIS Signs #Patent #License Agreement with #Taiwan #ODM

MicroVision, Inc. (NASDAQ: MVIS), a leader in innovative ultra-miniature projection display and sensing technology, today announced that it has signed a license agreement for its PicoP® scanning technology with a Taiwanese ODM.

MicroVision and the ODM have signed a patent license agreement under which the ODM has a license to make and sell Laser Beam Scanning (LBS) engines. The engines the ODM is making incorporate components it is purchasing from third parties. Under the agreement, MicroVision would receive a royalty payment from the ODM for each LBS engine the ODM sells. This agreement is related to MicroVision’s recently announced co-marketing relationship with STMicroelectronics.

“We are pleased to enter into a patent license with this ODM for our LBS technology,” said Bharath Rajagopalan, Vice President of Business Development and Marketing at MicroVision. “We believe this agreement demonstrates the value of MicroVision’s LBS intellectual property and provides for new opportunities and potential products for LBS technology in the market.”

About MicroVision

MicroVision is the creator of PicoP® scanning technology, an ultra-miniature laser projection and sensing solution based on the laser beam scanning methodology pioneered by the company. MicroVision’s platform approach for this advanced display and sensing solution means that it can be adapted to a wide array of applications and form factors. It is an advanced solution for a rapidly evolving, always-on world. Extensive research has led MicroVision to become an independently recognized leader in the development of intellectual property. MicroVision’s IP portfolio has been recognized by the Patent Board as a top 50 IP portfolio among global industrial companies and has been included in the Ocean Tomo 300 Patent Index. The company is based in Redmond, Wash.

For more information, visit the company’s website at www.microvision.com, on Facebook at www.facebook.com/MicroVisionInc or follow MicroVision on Twitter at @MicroVision.

MicroVision and PicoP are trademarks of MicroVision, Inc. in the United States and other countries. All other trademarks are the properties of their respective owners.

Forward-Looking Statements

Certain statements contained in this release, including those relating to royalty payments, future products and product applications are forward-looking statements that involve a number of risks and uncertainties. Factors that could cause actual results to differ materially from those projected in the company’s forward-looking statements include the following: our ability to raise additional capital when needed; products incorporating our PicoP® scanning technology may not achieve market acceptance, commercial partners may not perform under agreements as anticipated, we may be unsuccessful in identifying parties interested in paying any amounts or amounts we deem desirable for the purchase or license of IP assets, our or our customers failure to perform under open purchase orders; our financial and technical resources relative to those of our competitors; our ability to keep up with rapid technological change; government regulation of our technologies; our ability to enforce our intellectual property rights and protect our proprietary technologies; the ability to obtain additional contract awards; the timing of commercial product launches and delays in product development; the ability to achieve key technical milestones in key products; dependence on third parties to develop, manufacture, sell and market our products; potential product liability claims; and other risk factors identified from time to time in the company’s SEC reports, including the company’s Annual Report on Form 10-K filed with the SEC. Except as expressly required by federal securities laws, we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, changes in circumstances or any other reason.

$IMUC Reports Updated Immune Monitoring Data from #ICT107 #Glioblastoma

Long-Term Survival Data Reported from Phase 1 ICT-107 Trial

LOS ANGELES, Nov. 21, 2016  — ImmunoCellular Therapeutics, Ltd. (“ImmunoCellular”) (NYSE MKT:IMUC) announced the presentation of updated immune monitoring data from the phase 2 trial of ICT-107 in patients with newly diagnosed glioblastoma. Also presented were updated long-term survival data from the phase 1 trial of ICT-107. ICT-107 is a dendritic cell-based immunotherapy targeting multiple tumor-associated antigens on glioblastoma stem cells. ICT-107 is currently being tested in a phase 3 registration trial in patients with newly diagnosed glioblastoma. The updated phase 1 and phase 2 data were presented in two oral sessions on Friday, November 18^th, at the 21st Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology, held in Scottsdale, AZ.

The ICT-107 phase 2 trial was a randomized, double-blind, placebo-controlled phase 2 study of the safety and efficacy of ICT-107 in patients with newly diagnosed glioblastoma following resection and chemoradiation. ICT-107 is an intradermally administered autologous immunotherapy consisting of the patient’s own dendritic cells pulsed with six synthetic tumor-associated antigens: AIM-2, MAGE-1, TRP-2, gp100, HER-2, IL-13Rα2. The placebo control consisted of the patient’s unpulsed dendritic cells. The data from the phase 2 trial indicated a survival advantage in the ICT-107 treated group compared to the control group. The data also showed an association between immune response and survival, especially in HLA-A2 positive (HLA-A2+) patients, which is the target patient population for the ongoing phase 3 registration trial.

The updated immune response data from the phase 2 trial showed that treatment with ICT-107 resulted in the development of a measurable anti-tumor T cell response in some patients, which was associated with survival. Patients that developed the anti-tumor T cell response which was measurable by both ELISpot (to detect viable T cells capable of binding to a target antigen) and multimer testing (to detect T cell binding with higher sensitivity than ELISpot) had improved survival. The data demonstrated that immuno-monitoring can provide an early indication of patients responding to immunotherapy.  In the current ongoing phase 3 registration trial of ICT-107, ImmunoCellular plans to perform immuno-monitoring to support the trial.

The data were presented at SNO by Steven J. Swanson, PhD, Senior Vice President, Research, ImmunoCellular Therapeutics, in a presentation titled, “Categorizing immune responders with fusion metrics and simulation for association to survival and progression-free survival with immune response in HLA-A2+ patients with GBM from a phase 2 trial of dendritic cell (DC) immunotherapy (ICT-107).”

Dr. Swanson commented: “ICT-107 is designed to deliver therapeutic benefit by stimulating the patient’s immune system to attack tumor tissue. A first indicator that the immunotherapeutic is active is the production of tumor-specific T cells by the patient.  In our SNO presentation, we described our ability to more clearly interpret the immune-monitoring data from the phase 2 trial. The ability to accurately identify negative and positive responses enabled us to better understand which of the patients in our trial generated T cells capable of attacking the tumor. We determined that patients with a T cell response measureable in both the ELIspot assay and through multimer analysis achieved longer survival as compared with patients who did not show a positive response. These data should enable us to better interpret the results of our ongoing phase 3 trial.”

Andrew Gengos, ImmunoCellular Chief Executive Officer, said: “The phase 2 trial immune monitoring results indicate that patients who mount a T cell response appear to have improved survival over those without a detectable response.  In designing the phase 3 trial, we have made important changes in the protocol to potentially enhance the immune response in ICT-107 treated patients with the goal of optimizing the potential survival outcomes in the trial.”

Data from the phase 1 trial of ICT-107 were presented by Surasak Phuphanich, MD, Department of Neurology, Cedars-Sinai in Los Angeles, in a presentation titled “Ten-year follow up with long term remission in patients with newly diagnosed glioblastoma (GBM) treated with ICT-107 vaccine (phase 1).” The phase 1 open-label, single institution trial, which was completed in 2010, included 16 evaluable patients with newly diagnosed glioblastoma. Results of the study were initially published in 2012 (Cancer Immunol Immunother).

Updated survival data presented by Dr. Phuphanich at the 2016 SNO meeting showed that 19% of patients had long-term remission of greater than 8 years, with the longest remission being 9.6 years. Also, 38% of patients demonstrated long-term survival of greater than 8 years, with the longest survivor greater than 10.2 years. Immune response data showed a correlation between survival and cancer-stem-associated expression, and a trend toward greater CD8 T cell cytokine responses in long-term survivors.

ICT-107 Phase 3 Registration Trial Underway

The ongoing phase 3 registrational trial of ICT-107 is designed as a randomized, double-blind, placebo-controlled study of HLA-A2+ subjects, which is being conducted at about 120 sites in the US, Canada and the EU, with plans to randomize at least 500 patients with newly diagnosed glioblastoma. The primary endpoint in the trial is overall survival. Secondary endpoints include progression-free survival and safety, as well as overall survival in the two pre-specified MGMT subgroups.

For patients, families and physicians seeking additional information about the ICT-107 phase 3 trial, please consult www.clinicaltrials.gov.

About ImmunoCellular Therapeutics, Ltd.

ImmunoCellular Therapeutics, Ltd. is a Los Angeles-based clinical-stage company that is developing immune-based therapies for the treatment of brain and other cancers. The phase 3 registrational trial of lead product candidate, ICT-107, a patient-specific, dendritic cell-based immunotherapy targeting multiple tumor-associated antigens on glioblastoma stem cells, has been initiated. ImmunoCellular’s pipeline also includes: ICT-121, a patient-specific, dendritic cell-based immunotherapy targeting the CD133 antigen on stem cells in recurrent glioblastoma; ICT-140, a patient-specific, dendritic cell-based immunotherapy targeting antigens on ovarian cancer stem cells; and the Stem-to-T-cell research program which engineers the patient’s hematopoietic stem cells to generate antigen-specific cancer-killing T cells. To learn more about ImmunoCellular, please visit www.imuc.com.

Forward-Looking Statements for ImmunoCellular Therapeutics

This press release contains certain forward-looking statements, including statements regarding ImmunoCellular’s intentions and current expectations concerning, among other things, timing for enrollment and randomization of patients, the activation of clinical sites, the receipt and announcement of clinical data; the development and commercialization of ICT-107; the development of our preclinical Stem-to-T-cell program and ImmunoCellular’s ability to achieve its other clinical, operational and financial goals. Forward-looking statements are not guarantees of future performance and are subject to a number of risks and uncertainties, including the availability of resources to continue to develop ImmunoCellular’s product candidates, the uncertain timing of completion and success of clinical trials, and the risk that ICT-107 can be further successfully developed or commercialized.  Additional risks and uncertainties are described under the heading “Risk Factors” in ImmunoCellular’s most recently filed quarterly report on Form 10-Q and annual report on Form 10-K. Except as required by law, ImmunoCellular undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Contact:

ImmunoCellular Therapeutics, Ltd.
Investor Relations
Jane Green
415.348.0010 direct
415.652.4819 mobile
jane@jmgcomm.com